




(86) **Date de dépôt PCT/PCT Filing Date:** 2010/01/26
(87) **Date publication PCT/PCT Publication Date:** 2010/07/29
(45) **Date de délivrance/Issue Date:** 2018/08/21
(85) **Entrée phase nationale/National Entry:** 2011/07/14
(86) **N° demande PCT/PCT Application No.:** US 2010/022090
(87) **N° publication PCT/PCT Publication No.:** 2010/085797
(30) **Priorité/Priority:** 2009/01/26 (US61/147,270)

(51) **Cl.Int./Int.Cl.** **C07F 5/02** (2006.01),
A61K 31/155 (2006.01), **A61K 31/69** (2006.01),
A61K 49/00 (2006.01)
(72) **Inventeurs/Inventors:**
CHRISTIANSON, DAVID W., US;
TOMCZUK, BRUCE EDWARD, US;
POTTORF, RICHARD SCOTT, US;
COLASANTI, ANDREW VARGHA, US;
OLSON, GARY LEE, US
(73) **Propriétaires/Owners:**
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,
US;
CORRIDOR PHARMACEUTICALS, INC., US
(74) **Agent:** BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.


(54) **Titre : INHIBITEURS D'ARGINASE ET LEURS METHODES D'UTILISATION**

(54) **Title: ARGINASE INHIBITORS AND METHODS OF USE**



non-inhibitory lactone
"prodrug" form of the
inhibitor

active inhibitor
that fits in the
arginase active
site



(57) **Abrégé/Abstract:**

The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: $\text{H}_2\text{N}-\text{CH}(\text{R}_1)-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{B}(\text{OH})_2$ or $\text{H}_2\text{N}-\text{CH}(\text{R}_1)-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{B}(\text{OH})_2$ IA IB or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

(10) International Publication Number
WO 2010/085797 A3

FIG. 1

(57) Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB:
 $\text{H}_2\text{N}-\text{X}(\text{i})-\text{NH}_2$, $\text{X}=\{\begin{matrix}\text{xz}^+\backslash \\ \text{xz}^-/\end{matrix}$
 $\text{X}=\begin{matrix}\text{x}_2^+\\ ^+\text{R}_1\backslash\end{matrix}, \begin{matrix}/\\\text{R}_1\end{matrix}\text{KCOOH COOH}$ IA
 IB or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

WO 2010/085797 A3

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

4 November 2010

ARGINASE INHIBITORS AND METHODS OF USE

SUMMARY OF THE INVENTION


[0001] The present invention generally relates to enzyme inhibitors, particularly to arginase inhibitors, compositions containing these arginase inhibitors, and methods of their use for the treatment and diagnosis of conditions characterized either by abnormally high arginase activity or by abnormally low nitric oxide synthase activity.

[0002] There is a need for inhibitors of arginase activity, which are useful for treating diseases or disorders characterized either by abnormally high arginase activity in a tissue of a mammal or by abnormally low nitric oxide synthase activity in a tissue of the mammal. The methods, compositions, dosage forms, and kits of the present invention are directed toward these, as well as other, important ends.

[0003] The present invention, therefore, is directed to inhibitors of arginase activity, which are useful for treating diseases or disorders characterized either by abnormally high arginase activity in a tissue of a mammal or by abnormally low nitric oxide synthase activity in a tissue of the mammal.

[0004] Embodiments of the invention provide new inhibitors of arginase, especially α,α -disubstituted α -amino carboxylic acids, particularly L-amino acids. Without wishing to be bound by theory, it is suggested that, of the two substituents at the α -position, one binds to the enzyme active site, and the other α -position sidechain, which is referred to herein as R^1 , beneficially affects the pharmacological characteristics of the compound. Some exemplary embodiments of chemical structures of some arginase inhibitors of the invention are discussed below.

[0005] In one embodiment, the invention is directed to compounds of formula IA or formula IB:




or stereoisomers (especially the L-stereoisomers at the amino acid carbon), lactone prodrugs, or pharmaceutically-acceptable salts thereof;

wherein:

said dashed line represents an optional double bond;

Z is ;




X^1 is $-(CH_2)-$ or, when said double bond is present between X^1 and X^2 , X^1 is $-(CH)-$;

X^2 is $-(CH_2)-$ or $-(NR^2)-$, or, when said double bond is present between X^1 and X^2 or between X^2 and X^3 , X^2 is $-(CH)-$ or N;

X^3 is $-(CH_2)-$, a heteroatom moiety selected from the group consisting of $-S-$, $-O-$ and $-(NR^2)-$ or, when said double bond is present between X^2 and X^3 or between X^3 and X^4 , X^3 is $-(CH)=$ or N;

X^4 is $-(CH_2)-$ or, when said double bond is present between X^3 and X^4 , X^4 is $-(CH)-$ and is in the trans configuration;

provided that not more than one of X^2 and X^3 is said $-(NR^2)-$ or said heteroatom moiety;



provided that X^3 is $-(NR^2)-$ when Z is


provided that there are no more than two double bonds between X^1 , X^2 , X^3 , and X^4 and no two double bonds share a common carbon atom;

R^1 is a monovalent moiety other than H; or R^1 and said α -carboxylate, when taken together,

form a lactone; and

R^2 is, independently, H, methyl, or ethyl.

[0006] In certain preferred embodiments, the compounds of formula IA and IB are the L-stereoisomer forms (as illustrated below) of the compounds, defined herein as compounds of formula Ia and Ib, respectively:



[0007] Structural and functional studies conducted by the inventors have established that the “L” stereochemistry of each amino acid (as defined immediately above) is required for tight binding in the enzyme active site; “D” stereoisomers do not bind as tightly or are less efficacious.

[0008] In certain embodiments,

R^1 is (C_1-C_{20}) alkyl, hydroxy (C_1-C_{20}) alkyl, hydroxy (C_2-C_{20}) alkenyl, (C_2-C_{20}) alkenyl, (C_2-C_{20}) alkynyl, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; (C_5-C_{50}) aryl (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroaryl (C_1-C_{20}) alkyl, (C_2-C_{50}) heterocycloalkyl (C_1-C_{50}) alkyl, (C_5-C_{50}) aryloxy (C_1-C_{20}) alkyl, (C_5-C_{50}) arylthio (C_1-C_{50}) alkyl, (C_3-C_{50}) heteroaryloxy (C_1-C_{20}) alkyl, (C_5-C_{50}) arylamino (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroarylamino (C_1-C_{20}) alkyl, amino (C_1-C_{20}) alkyl, $-R^x-C(=O)-R^y$, $-R^x-O-R^z$, $-R^x-O-R^x-NR^3R^5$, $-R^x-NR^3R^5$, $-R^x-O-C(=O)-R^y$, (C_1-C_6) alkyl-B-(OH)₂, -L-Y, or labeled derivative thereof; or R^1 and said α -carboxylate, when taken together, form a lactone having 4 to 7 ring atoms;

each R^x is independently (C_1-C_{20}) alkylenyl;

R^y is (C_1-C_6) alkyl, (C_5-C_{50}) aryl (C_1-C_6) alkyl, (C_5-C_{50}) aryloxy (C_1-C_6) alkyl, hydroxyl, (C_1-C_6) alkoxy, (C_3-C_8) cycloalkyl, $N(R^3)_2$, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; heterocyclyl, (C_5-C_{50}) aryl (C_1-C_6) alkyl, or (C_3-C_{50}) heteroaryl (C_1-C_6) alkyl;

R^z is (C_1-C_6) alkyl, (C_3-C_8) cycloalkyl, $-R^x-O-(C_1-C_6)$ alkyl, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl

having at least one heteroatom selected from N, O, and S; (C₅-C₅₀)aryl(C₁-C₆)alkyl, or (C₃-C₅₀)heteroaryl(C₁-C₆)alkyl;

R³ is, independently, H, (C₁-C₆)alkyl, or (C₁-C₆)alkyl-N(R⁴)₂;

R⁴ is, independently, H or (C₁-C₆)alkyl;

R⁵ is -C(=O)-(C₁-C₆)alkyl, -C(=O)-(C₅-C₅₀)aryl, -SO₂-(C₅-C₅₀)aryl, -C(=O)NR³R⁴, -C(=O)-NR⁴(C₅-C₅₀)aryl, or -C(=O)-heterocycle;

or R³ and R⁵ together form a (C₂-C₁₀)heterocycloalkyl;

L is an aliphatic or aromatic linkage; and

Y is a residue of an imageable moiety, peptide, peptidomimetic, or carbohydrate.

[0009] In other embodiments, the invention is directed to compositions, comprising:

at least one compound of the invention or a pharmaceutically acceptable salt thereof; and
a pharmaceutically-acceptable carrier.

[0010] In yet other embodiments, the invention is directed to methods of inhibiting arginase in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

[0011] In yet other embodiments, the invention is directed to methods of treating an arginase-related disorder in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

[0012] In other embodiments, the invention is directed to methods of diagnosing arginase over-expression in a patient, comprising the step of:

administering to said patient a diagnostically-effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof;

where R¹ is a labeled derivative thereof; and

imaging said patient.

[0013] In other aspects, the invention is directed to methods of diagnosing arginase over-expression in a patient, comprising the step of:

administering to said patient a diagnostically-effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof;

where Y is an imageable moiety; and

imaging said patient.

[0014] In certain aspects, the invention is directed to methods for radioimaging a patient, comprising the steps of:

administering to said patient an effective amount of a compound of the invention;

wherein Y is an imageable moiety; and

scanning said patient using a radioimaging device.

[0015] In certain aspects, the invention is directed to methods of inhibiting arginase, comprising the step of:

contacting said arginase with a compound of the invention or a salt thereof. In certain embodiments, the arginase is a yeast, bacterial, parasitic, or mammalian arginase. In certain other embodiments, the mammalian arginase is human type I arginase or human type II arginase (e.g., human penile arginase).

[0016] In certain aspects, the invention is directed to diagnostic compositions, comprising:

a diagnostically-effective amount of the compound of the invention or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier;

where R¹ is a labeled derivative thereof.

[0017] In certain aspects, the invention is directed to diagnostic compositions, comprising:

a diagnostically-effective amount of the compound of the invention or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier;

where Y is an imageable moiety.

[0018] In certain embodiments, the invention is directed to methods of treating a disease or condition associated with up-regulation of arginase in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of the invention or a

pharmaceutically acceptable salt thereof;

wherein said disease or condition is a gastrointestinal disease, a pulmonary inflammatory disease, a sexual arousal disorder, a cardiovascular disorder, a hemolytic disorder, an autoimmune disease, wound healing, a disease caused by parasitic protozoa, a disease caused by bacteria, a cancer, pre-term labor, psoriasis, or a combination thereof.

[0019] In certain embodiments, the invention is directed to methods of providing relief from immune suppression in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof;

wherein said mammal is suffering from a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.


[0020] In certain embodiments, the invention is directed to methods of inhibiting the production of ornithine in a mammal suffering from at least one tumor, comprising the step of:

administering to said mammal an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

[0021] In certain embodiments, the invention is directed to compositions, comprising:

a compound of formula Ia or formula Ib or a pharmaceutically acceptable salt thereof;
 a phosphodiesterase-1 (PDE1) inhibitor, a phosphodiesterase-2 (PDE2) inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, or a non-specific PDE inhibitor that inhibits PDE1, PDE2, PDE5, or a combination thereof; and
 optional pharmaceutically-acceptable excipient.

[0022] Synthesis of α,α -disubstituted amino acids is well known to be difficult, at least in part because the α -nitrogen atom can act as a nucleophile and therefore interfere with alkylation of the α -carbon atom. In order to temporarily mask this functionality, the nitrogen atom is protected with diphenylmethylene group, which does not interfere with the subsequent alkylation and, in some cases, hydroboration. Accordingly, in certain embodiments, the invention is directed to processes for preparing a substituted boronic acid of formula I:




I ;

or stereoisomer, lactone prodrug, or pharmaceutically-acceptable salt thereof;

said process comprising:

reacting in a solution phase, in the presence of an iridium catalyst, preferably $[\text{Ir}(\text{cod})\text{Cl}]_2$, 4,4,5,5-tetramethyl-1,3,2-dioxaborolane with a compound of formula II:




II

to form a boronate ester product; and

deprotecting said boronate ester product, preferably with a strong aqueous acid, to form said compound of formula I;

wherein:

R is methyl, ethyl, or t-butyl;



Z is ;

X^1 is $-(\text{CH}_2)-$;

X^2 is $-(\text{CH}_2)-$;

X^3 is $-(\text{CH}_2)-$;

X^4 is $-(\text{CH}_2)-$;

R¹ is a monovalent moiety other than H; or R¹ and said α -carboxylate, when taken together, form a lactone.

DETAILED DESCRIPTION OF THE INVENTION

[0023] Embodiments of the present invention relates to enzyme inhibitors, particularly to arginase inhibitors, compositions thereof, and methods of their use for the treatment and diagnosis of conditions characterized either by abnormally high arginase activity or by abnormally low nitric oxide synthase activity.

Definitions

[0024] As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings.

[0025] As used herein, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly indicates otherwise.

[0026] As used herein, the term “about,” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of $\pm 20\%$, preferably $\pm 10\%$, more preferably $\pm 5\%$, even more preferably $\pm 1\%$, and yet even more preferably $\pm 0.1\%$ from the specified value, as such variations are appropriate to perform the disclosed methods and compositions.

[0027] As used herein, “administering” refers to the act of giving or providing a composition or compound to a patient by the patient themselves or by a caregiver, such as a medical professional or the like, including the act of ingestion by or application to the patient or the like wherein the composition or compound can exert its effects.

[0028] As used herein, “effective amount” refers to an amount of the active ingredient as described herein that may be effective to prevent, reduce or eliminate the symptoms or condition.

[0029] As used herein, “treating” and “treatment” refer to the preventative, curative, and palliative treatment of a condition, malady or affliction, especially in a human patient in need of such treatment.

[0030] As used herein, “pharmaceutically-acceptable” refers to those compounds, materials, compositions, or dosage forms that are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.

[0031] As used herein, “pharmaceutically-acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof, including acid addition salts and base addition salts. Examples of pharmaceutically-acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The term “acid addition salt” refers to the corresponding salt derivative of a parent compound that has been prepared by the addition of an acid. The pharmaceutically-acceptable salts include the conventional salts or the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic acids. For example, such conventional salts include, but are not limited to, those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, adipic, alginic, aspartic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, benzenesulfonic, toluenesulfonic, methanesulfonic, 2-naphthalenesulfonic, ethane disulfonic, oxalic, isethionic, glucoheptanoic, glycerophosphoric, hemisulfanic, heptanoic, hexanoic, hydrochloric, hydrobromic, hydroiodic, 2-hydroxyethanesulfonic, 2-naphthalenesulfonic, pectinic, phosphoric, sulfuric, 3-phenylpropionic, picric, pivalic, thiocyanic, *p*-toluenesulfonic, butyric, camphoric, camphorsulfonic, digluconic, cyclopentanepropionic, bisulfuric, dodecylsulfuric, ethanesulfonic, and undecanoic and the like. Thus, the term “base addition salt” refers to the corresponding salt derivative of a parent compound that has been prepared by the addition of a base. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and

butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. The pharmaceutically-acceptable salts include the conventional salts or the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic bases. For example, such conventional salts include, but are not limited to, those derived from inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide and ammonium hydroxide and the salts prepared from organic amines, such as methyl amine, ethyl amine, isopropyl amine, piperidine, piperazine, pyrrolidine, ethanolamine, morpholine, diazepam, ethylene diamine, pyridine, quinoline, quinuclidine, and the like.

[0032] As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0033] As used herein, “dosage unit” refers to physically discrete units suited as unitary dosages for the particular patient to be treated. Each unit may contain a predetermined quantity of active compound(s) calculated to produce the desired therapeutic effect(s) in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention may be dictated by (a) the unique characteristics of the active compound(s) and the particular therapeutic effect(s) to be achieved, and (b) the limitations inherent in the art of compounding such active compound(s).

[0034] As used herein, “patient” refers to an animal, including a mammal, preferably a human.

[0035] R^a , as used herein, is, independently, H, OH, alkyl (optionally substituted with one or more R^4), alkoxy (optionally substituted with one or more R^4), halo, trifluoromethyl, alkanoyloxy (optionally substituted with one or more R^4), methylenedioxy, benzyloxy (optionally substituted with one or more R^4), phenyloxy (optionally substituted with one or more

R⁴), naphthyloxy (optionally substituted with one or more R⁴), nitro, trifluoromethoxy, nitrile, alkenyl (optionally substituted with one or more R⁴), alkynyl, sulfoxide, sulfonyl, sulfonamido, aryl (optionally substituted with one or more R⁴), heteroaryl (optionally substituted with one or more R⁴), aryloyl (optionally substituted with one or more R⁴), heteroaryloyl (optionally substituted with one or more R⁴), heteroaryloxy (optionally substituted with one or more R⁴), heteroarylmethoxy (optionally substituted with one or more R⁴), alkanoyl, alkoxycarbonyl, alkylaminocarbonyl, or amino. R⁴ is (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, (C₂-C₂₀)alkynyl, halo, nitrile, nitro, (C₅-C₅₀)aryl, (C₃-C₅₀)heteroaryl having at least one heteroatom selected from N, O, and S; (C₅-C₅₀)aryl(C₁-C₂₀)alkyl, heteroaryl(C₁-C₂₀)alkyl, (C₅-C₅₀)aryloxy(C₁-C₂₀)alkyl, heteroaryloxy(C₁-C₂₀)alkyl, (C₅-C₅₀)arylamino(C₁-C₂₀)alkyl, heteroarylamino(C₁-C₂₀)alkyl, amino(C₁-C₂₀)alkyl, -R^x-C(=O)-R^y, or -R^x-O-R^z, -L-Y.

[0036] “Alkyl,” as used herein, refers to an aliphatic hydrocarbon chain of 1 to about 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably, 1 to 6 carbon atoms, and even more preferably, 1 to 4 carbon atoms and includes straight and branched chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *sec*-butyl, *tert*-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl. Lower alkyl refers to alkyl having 1 to 4 carbon atoms. Alkyl groups can be optionally substituted with one or more R^a, as defined herein.

[0037] “Alkylene,” as used herein, refers to a divalent counterpart of “alkyl,” as defined herein (e.g., methylene, ethylene, propylene, etc.). Alkylene groups can be optionally substituted with one or more R^a, as defined herein.

[0038] “Alkenyl” or “olefinic,” as used herein, refers to an alkyl group of at least two carbon atoms having one or more double bonds, wherein alkyl is as defined herein. Alkenyl groups can be optionally substituted with one or more R^a, as defined herein.

[0039] “Hydroxy(C₁-C₂₀)alkyl,” as used herein, refers to an alkyl group, as defined herein, substituted with at least one hydroxy group.

[0040] “Hydroxy(C₂-C₂₀)alkenyl,” as used herein, refers to an alkenyl group, as defined herein, substituted with at least one hydroxy group.

[0041] “Alkynyl,” as used herein, refers to an alkyl group of at least two carbon atoms having one or more triple bonds, wherein alkyl is as defined herein. Alkynyl groups can be optionally substituted with one or more R^a, as defined herein.

[0042] “Aryl” as used herein, refers to an optionally substituted, mono-, di-, tri-, or other multicyclic aromatic ring system having from about 5 to about 50 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 6 to about 10 carbons being preferred. Non-limiting examples include, for example, phenyl, naphthyl, anthracenyl, and phenanthrenyl. Aryl groups can be optionally substituted with one or more R^a, as defined herein.

[0043] “Heteroaryl,” as used herein, refers to an optionally substituted, mono-, di-, tri-, or other multicyclic aromatic ring system that includes at least one, and preferably from 1 to about 4 sulfur, oxygen, or nitrogen heteroatom ring members. Heteroaryl groups can have, for example, from about 3 to about 50 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 4 to about 10 carbons being preferred. Non-limiting examples of heteroaryl groups include, for example, pyrrolyl, furyl, pyridyl, 1,2,4-thiadiazolyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, thiophenyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, purinyl, carbazolyl, benzimidazolyl, and isoxazolyl. Heteroaryl groups can be optionally substituted with one or with one or more R^a, as defined herein.

[0044] “(C₅-C₅₀)Aryl(C₁-C₂₀)alkyl,” as used herein, refers to the group R-R’- where R is an aryl group and R’ is an alkylenyl, as defined herein.

[0045] “Heteroaryl(C₁-C₂₀)alkyl,” as used herein, refers to the group R-R’- where R is a heteroaryl group and R’ is an alkylenyl, as defined herein.

[0046] “(C₅-C₅₀)aryloxy(C₁-C₂₀)alkyl,” as used herein, refers to the group R-O-R’- where R is an aryl group and R’ is an alkylenyl, as defined herein.

[0047] “Heteroaryloxy(C₁-C₂₀)alkyl,” as used herein, refers to the group R-O-R’- where R is a heteroaryl group and R’ is an alkylenyl, as defined herein.

[0048] “(C₅-C₅₀)arylamino(C₁-C₂₀)alkyl,” as used herein, refers to the group R-NH-R’ - where R is an aryl group and R’ is an alkylenyl, as defined herein.

[0049] “Heteroaryloxyamino(C₁-C₂₀)alkyl,” as used herein, refers to the group R-NH-R’ - where R is a heteroaryl group and R’ is an alkylenyl, as defined herein.

[0050] “Amino(C₁-C₂₀)alkyl,” as used herein, refers to the group N(R’)-R’ - where R’ is a hydrogen or (C₁-C₆)alkyl group and R’ is an alkylenyl, as defined herein.

[0051] “Cycloalkyl,” as used herein, refers to an optionally substituted, alkyl group having one or more rings in their structures having from 3 to about 20 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from 3 to about 10 carbon atoms being preferred. Multi-ring structures may be bridged or fused ring structures. Groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, 2-[4-isopropyl-1-methyl-7-oxa-bicyclo[2.2.1]heptanyl], 2-[1,2,3,4-tetrahydro-naphthalenyl], and adamantyl.

[0052] “Heterocycloalkyl,” as used herein, refers to an optionally substituted, cycloalkyl group having one or more rings in their structures having from 2 to about 20 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from 2 to about 10 carbon atoms being preferred, in addition to at least one heteroatom independently selected from the group consisting of N, O and S. Multi-ring structures may be bridged or fused ring structures. Groups include, but are not limited, to aziridinyl, pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, and pyranlyl.

[0053] “Halo” or “halogen,” as used herein, refers to chloro, bromo, fluoro, and iodo.

[0054] “Alkoxy,” as used herein, refers to the group R-O- where R is an alkyl group of 1 to 6 carbon atoms.

[0055] “Alkoxycarbonyl,” as used herein, refers to the group R-O-C(=O)- where R is an alkyl group of 1 to 6 carbon atoms.

[0056] “Alkanoyl,” as used herein, refers to the group $R-C(=O)-$ where R is an alkyl group of 1 to 6 carbon atoms.

[0057] “Alkanoyloxy,” as used herein, refers to the group $R-C(=O)-O-$ where R is an alkyl group of 1 to 6 carbon atoms.

[0058] “Alkylaminocarbonyl,” as used herein, refers to the group $R-NH-C(=O)-$ where R is an alkyl group of 1 to 6 carbon atoms.

[0059] “Alkylcarbonylamino,” as used herein, refers to the group $R-C(=O)-NH$ where R is an alkyl group of 1 to 6 carbon atoms.

[0060] “Heteroarylmethyl,” as used herein, refers to the group $R-CH_2-$ where R is a heteroaryl group, as defined herein.

[0061] “Heteroarylmethyloxy,” as used herein, refers to the group $R-CH_2-O-$ where R is a heteroaryl group, as defined herein.

[0062] “Heteroaryloxy,” as used herein, refers to the group $R-O-$ where R is a heteroaryl group, as defined herein.

[0063] “Heteroarylmethyloxy,” as used herein, refers to the group $R-CH_2-O-$ where R is a heteroaryl group, as defined herein.

[0064] “Heterocycle” or “heterocyclyl,” as used herein, refers to a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring, or radical thereof, that is saturated, partially unsaturated or unsaturated (aromatic), and which contains carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen atom in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds one, then these heteroatoms are not adjacent to one

another. It is preferred that the total number of S and O atoms in the heterocycle is not more than one. Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2 dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinoliziny, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4H-carbazolyl, α -, β -, or γ -carbolinyl, chromanyl, chromenyl, cinnoliny, decahydroquinoliny, 2H,6H-1,5,2 dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazoliny, imidazolyl, 1H-indazolyl, indolenyl, indoliny, indoliziny, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindoliny, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, morpholiny, naphthyridiny, octahydroisoquinoliny, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl., oxazolyl, oxazolidinylpyrimidinyl, phenanthridiny, phenanthroliny, phenoxazinyl, phenazinyl, phenothiazinyl, phenoxathiiny, phenoxazinyl, phthalazinyl, piperazinyl, piperidiny, pteridiny, piperidonyl, 4-piperidonyl, pteridiny, puriny, pyranyl, pyraziny, pyrazolidinyl, pyrazoliny, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridiny, pyridyl, pyrimidinyl, pyrrolidinyl, pyrroliny, pyrrolyl, quinazoliny, quinoliny, 4H-quinoliziny, quinoxaliny, quinuclidiny, carboliny, tetrahydrofuranyl, tetrahydroisoquinoliny, tetrahydroquinoliny, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred heterocycles include, but are not limited to, pyridiny, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazoliny, or isatiny. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

[0065] “Sulfoxide,” as used herein, refers to a compound or moiety containing the group -S(=O)-.

[0066] “Sulfonamido,” as used herein, refers to a moiety containing the group -S(O)₂-NH-.

[0067] “Sulfonyl,” as used herein, refers to a moiety containing the group -S(O)₂-.

[0068] “Aliphatic linkage,” as used herein, refers to any divalent alkylene group (e.g., methylene, ethylene, propylene, etc.), including groups having the general formula $-(CH_2)_m-$, wherein m is an integer from 1 to 6.

[0069] “Aromatic linkage,” as used herein, refers to any divalent aryl group, such as a $-(C_6H_4)-$ group.

[0070] “Residue of an imageable moiety,” or simply “imageable moiety,” as used herein, refers to any moiety, as generally known in the art and as specifically defined herein, that comprises one or more groups capable of detection either directly or indirectly in an *in vivo* or *in vitro* diagnostic imaging procedure, and comprises, e.g., one or more moieties that emit or may be caused to emit detectable radiation (e.g., by radioactive decay, fluorescence excitation, spin resonance excitation, etc.), groups that affect local electromagnetic fields (e.g., paramagnetic, superparamagnetic, ferromagnetic, or ferromagnetic species), groups that absorb or scatter radiation energy (e.g., chromophores, particles (including gas or liquid containing vesicles), heavy elements and compounds thereof, etc.), and groups that generate a detectable substance (e.g., gas microbubble generators). Examples of imageable moieties may be selected from the group consisting of a gamma ray emitting radioisotopes, positron emitting radioisotopes, a magnetic resonance imaging contrast agents (e.g., gadolinium chelates), X-ray contrast agents (e.g., iodinated radioopaque aromatic compounds), or an ultrasound contrast agent (e.g., liposomes comprising an echogenic compound).

[0071] “Peptide,” as used herein, means a linear compound that consists of two or more amino acids (as defined herein) that are linked by means of a peptide bond. A “peptide” as used in the presently claimed invention is intended to refer to a moiety with a molecular weight of less than about 10,000 Daltons, preferable less than about 5,000 Daltons, and more preferably less than about 2,500 Daltons. The term “peptide” also includes compounds containing both peptide and non-peptide components, such as pseudopeptide or peptidomimetic residues or other non-amino acid components. Such a compound containing both peptide and non-peptide components may also be referred to as a “peptide analog.” A “residue of peptide” means that a molecule where a portion of a peptide has been removed to accommodate a bond to another molecule, such as in the R^1 group of the compounds of the invention.

[0072] “Pseudopeptide” or “peptidomimetic,” as used herein, means a compound that mimics the structure of an amino acid residue or a peptide, for example, by using linking groups other than amide linkages between the peptide mimetic and an amino acid residue (pseudopeptide bonds) or by using non-amino acid substituents or a modified amino acid residue. A “residue of peptidomimetic” means that a molecule where a portion of a pseudopeptide or peptidomimetic has been removed to accommodate a bond to another molecule, such as in the R¹ group of the compounds of the invention.

[0073] “Carbohydrate,” as used herein, means an organic compound having aldehydes or ketones with many hydroxyl groups added, usually one on each carbon atom that is not part of the aldehyde or ketone functional group, including sugars, starches, celluloses, and gums. A “residue of carbohydrate” means that a molecule where a portion of a carbohydrate has been removed to accommodate a bond to another molecule, such as in the R¹ group of the compounds of the invention.

Biological Activity of Arginase

[0074] Each individual excretes roughly ten kilograms of urea per year, as a result of the hydrolysis of arginine in the final cytosolic step of the urea cycle. The activity of the liver enzyme, arginase, permits disposal of nitrogenous wastes that result from protein catabolism. In tissues lacking a complete complement of the enzymes that catalyze the reactions of the urea cycle, arginase regulates cellular concentrations of arginine and ornithine, which are used for biosynthetic reactions. Arginine is used, by way of example, in the synthesis of nitric oxide. In macrophages, arginase activity is reciprocally coordinated with the activity of the enzyme, nitric oxide synthase. Reciprocal coordination of the activities of arginase and nitric oxide synthase (NOS) modulates NO-dependent cytotoxicity.

[0075] Arginase catalyzes divalent cation-dependent hydrolysis of L-arginine to form L-ornithine and urea. The enzyme is currently known to serve three important functions: (1) production of urea, (2) production of ornithine, and (3) regulation of substrate arginine levels for nitric oxide synthase. Urea production provides a mechanism to excrete nitrogen in the form of a highly soluble, non-toxic compound, thus avoiding the potentially dangerous consequences of high

ammonia levels. L-Ornithine is a precursor for the biosynthesis of polyamines, spermine, and spermidine, which have important roles in cell proliferation and differentiation. Finally, arginase modulates production of nitric oxide by regulating the levels of arginine present within tissues.

[0076] Synthesis and evaluation of non-reactive arginine analogs for use as enzyme inhibitors or receptor antagonists is a rapidly growing area of medicinal chemical research. Since both NO synthase and arginase compete for the same substrate, the possibility of reciprocal regulation of both arginine metabolic pathways has been explored. Furthermore, *N*^ω-hydroxy-L-arginine (L-HO-Arg), an intermediate in the NO synthase reaction, is an endogenous arginase inhibitor. The phenomenon of reciprocal regulation between arginase and NO synthase has only recently been examined. In the internal anal sphincter (IAS), it was shown that exogenous administration of arginase attenuates NO synthase-mediated non-adrenergic and non-cholinergic (NANC) nerve-mediated relaxation.

[0077] As discussed in more detail below, an excess of arginase has also recently been associated with a number of pathological conditions that include gastric cancer, certain forms of liver injury, and pulmonary hypertension following orthotopic liver transplantation. Furthermore, high levels of arginase can cause impairment in NANC-mediated relaxation of the IAS. Previous studies have demonstrated that arginase pre-treatment causes significant suppression of the NANC nerve-mediated relaxation of the IAS that is mediated primarily via the L-arginine-NO synthase pathway. Impairment in NANC relaxation by excess arginase may be related to L-arginine depletion. Furthermore, suppressed relaxation could be restored by the arginase inhibitor L-HO-Arg. It is possible, therefore, that patients with certain conditions associated with an increase in arginase activity may stand to benefit from treatment with arginase inhibitors. However, an arginase inhibitor such as L-OH-Arg can not be selective since it also serves as a NO synthase substrate. Because of this, the exact role of arginase in pathophysiology and the potential therapeutic actions of arginase inhibitors remains undetermined.


[0078] The X-ray crystal structure of rat liver arginase is available. Rat liver arginase is a trimeric metalloenzyme which contains a bi-nuclear manganese cluster in the active site of each subunit. This bi-nuclear cluster is required for maximal catalytic activity. X-ray crystal structures of human arginase I and human arginase II are also available. See, e.g., Di Costanzo

et al., Proc. Natl. Acad. Sci. (USA) 102, 13058 (2005) (X-ray crystal structures of human arginase I); and Cama et al., Biochemistry 42, 8445 (2003) (X-ray crystal structures of human arginase II). Similarly, several structural analyses and modeling studies have been performed using three-dimensional crystal structures of arginase-inhibitor complexes, including the inhibitors illustrated in Scheme 18. See, e.g., Cox et al., Nat. Struct. Biol. 6, 1043 (1999) (rat arginase I complexed with 2(*S*)-amino-6-borono-hexanoic acid (“ABH”)); Kim et al., Biochemistry 40, 2678 (2001) (rat arginase I complexed with *S*-(2-boronoethyl)-l-cysteine (“BEC”)); Cox et al., Biochemistry 40, 2689 (2001) (rat arginase I complexed with N^ω-hydroxy-nor-l-arginine (“nor-NOHA”)); DiConstanzo et al., Proc. Natl. Acad. Sci. (USA) 102, 13058 (2005) (human arginase I complexed with ABH and BEC); and Cama et al., Biochemistry 42, 8445 (2003) (human arginase II complexed with BEC).

Arginase Inhibitors

[0079] In view of the foregoing modeling studies and based on the discoveries described herein, new α -amino acid arginase inhibitors that are modified at the C α position, thereby generating heretofore unknown molecular entities that bind to arginase I and arginase II, including human arginases, are provided herein. The C α -R¹ groups of the invention replace the C α -H groups of the parent compounds, namely ABH, BEC, and nor-NOHA, which are illustrated in Scheme 18. It should be appreciated that the addition of the R¹ groups can be selected to target binding interactions in the outer active site cleft and the region flanking the outer active site clefts of parasitic arginase, bacterial arginase, and arginases I and II. Without intending to be bound by theory, the inventors suggest that these R¹-substituted compounds have increased interactions with the target protein(s) that result in increased potencies or selectivities (or both) over compounds in the prior art.


[0080] Embodiments of the present invention therefore is directed, in part, to compounds of formula IA or formula IB:



or stereoisomers (especially the L stereoisomers of the amino acid), lactone prodrugs, or pharmaceutically-acceptable salts thereof;

wherein:

said dashed line represents an optional double bond;




X^1 is $-(CH_2)-$ or, when said double bond is present between X^1 and X^2 , X^1 is $-(CH)-$;
 X^2 is $-(CH_2)-$ or $-(NR^2)-$, or, when said double bond is present between X^1 and X^2 or between X^2 and X^3 , X^2 is $-(CH)-$ or N;

X^3 is $-(CH_2)-$, a heteroatom moiety selected from the group consisting of $-S-$, $-O-$ and $-(NR^2)-$ or, when said double bond is present between X^2 and X^3 or between X^3 and X^4 , X^3 is $-(CH)-$ or N;

X^4 is $-(CH_2)-$ or, when said double bond is present between X^3 and X^4 , X^4 is $-(CH)-$ and is in the trans configuration;

provided that not more than one of X^2 and X^3 is said $-(NR^2)-$ or said heteroatom moiety;



provided that X^3 is $-(NR^2)-$ when Z is


provided that there are no more than two double bonds between X^1 , X^2 , X^3 , and X^4 and no two double bonds share a common carbon atom;

R^1 is a monovalent moiety other than H; or R^1 and said α -carboxylate, when taken together, form a lactone; and

R^2 is, independently, H, methyl, or ethyl.

[0081] Some examples of suitable R^1 groups are presented in Schemes 19-24 hereinbelow.


[0082] In certain preferred embodiments, the compounds of formula IA and IB are the L-stereoisomer forms (as illustrated below) of the compounds, defined herein as compounds of formula Ia and Ib, respectively:



[0083] Structural and functional studies conducted by the inventors have established that the “L” stereochemistry of each amino acid (as defined immediately above) is required for tight binding in the enzyme active site; “D” stereoisomers do not bind as tightly or are less efficacious. Alternatively stated, the preferred stereochemistry is analogous to the stereospecific replacement of the (*R*)-hydrogen in ABH (see Scheme 18) by R^1 . Of course, depending on the relative priority of the two substituents at the quaternary $C\alpha$, the compound could have either *R*- or *S*-stereochemistry. In preferred compounds, the *S*-stereochemistry generally occurs only in a limited case, typically when R^1 is a lower priority group, such as methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, and iso-butyl. For groups that are generally larger than n-butyl, the stereochemistry is *R*. Typically when comparing the inhibitory activities of the *R*- and *S*-stereoisomers, one will be more active than the other, and therefore the preferred stereochemistry is the form that more effectively permits the molecule to function as an arginase inhibitor. Indeed, structural and functional studies have established that the αC stereochemistry as defined immediately above is preferred for tight binding in the enzyme active site; whereas stereoisomers with the opposite configuration do not bind as tightly or are less efficacious.

[0084] Alternatively, the stereoisomers may be defined where the ProS hydrogen of glycine depicted below is replaced by an R^1 side chain that fits into the enzyme active site. In the compounds of formulas IA and IB, R^1 replaces the ProR hydrogen of glycine. According to the Cahn-Ingold-Prelog rules, the designation *R* or *S* for the stereoisomers depends upon the hierarchy based on the atoms connected to the chiral carbon. For instance, if R^1 is methyl and

$X^1 \dots$ is $-(CH_2)_4B(OH)_2$ then the chirality will be *S*. However, if R^1 is methyl and $X^1 \dots$ is $-(CH_2)S(CH_2)_2B(OH)_2$ then the chirality will be *R*. Additionally, if R^1 is $(CH_2)OH$ and $X^1 \dots$ is $-(CH_2)_4B(OH)_2$ then the chirality will be *R*.



[0085] One skilled in the art will appreciate that the syntheses of such R^1 groups at the α -position of an amino acid is a difficult synthetic process as judged by the lack of commercially available α,α -disubstituted amino acids. See, e.g., Vogt et al., *Org. Biomol. Chem.* 5, 406-30 (2007). As has been demonstrated in the synthetic schemes discussed herein, one or both of the R^1 and boronoalkyl side chains needs to be introduced via alkylation reactions onto a suitably protected amino acid scaffold. In fact, the chemistry described herein discloses a novel process of hydroboration of a crotyl group to produce the requisite terminal boronic acids in an amino acid scaffold. See, Yamamoto et al., *Tetrahedron* 60, 10695-700 (2004).

[0086] It should also be appreciated that the addition of the R^1 group to the known boronic acid- and *N*-hydroxy guanidine-type inhibitors can be selected to target binding interactions in the outer active site cleft and the region flanking the outer active site clefts of parasitic arginase, bacterial arginase, and arginases I and II. These R^1 substituted compounds would have increased interactions with the target protein which would result in increased potencies or selectivities over the prior art. Furthermore, it should be appreciated that the syntheses of these R^1 groups at the α -position of an amino acid is a difficult synthetic process as judged by the lack of commercially available α,α -disubstituted amino acids. See, Vogt et al., *Org. Biomol. Chem.* 5, 406-30 (2007).

[0087] As is demonstrated in the synthetic schemes discussed below, one or both of the R^1 and boronoalkyl side chains needs to be introduced via alkylation reactions onto a suitably protected amino acid scaffold. In fact, the chemistry described herein discloses a novel process of hydroboration of a crotyl group to produce the requisite terminal boronic acids in an amino acid scaffold. See, Yamamoto et al., *Tetrahedron* 60, 10695-700 (2004).

[0088] In certain particular embodiments,

R^1 is (C_1-C_{20}) alkyl, hydroxy (C_1-C_{20}) alkyl, hydroxy (C_2-C_{20}) alkenyl, (C_2-C_{20}) alkenyl, (C_2-C_{20}) alkynyl, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; (C_5-C_{50}) aryl (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroaryl (C_1-C_{20}) alkyl, (C_2-C_{50}) heterocycloalkyl (C_1-C_{20}) alkyl, (C_5-C_{50}) aryloxy (C_1-C_{20}) alkyl, (C_5-C_{50}) arylthio (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroaryloxy (C_1-C_{20}) alkyl, (C_5-C_{50}) arylamino (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroarylamino (C_1-C_{20}) alkyl, amino (C_1-C_{20}) alkyl, $-R^x-C(=O)-R^y$, $-R^x-O-R^z$, $-R^x-O-R^x-NR^3R^5$, $-R^x-NR^3R^5$, $-R^x-O-C(=O)-R^y$, (C_1-C_6) alkyl-B-(OH)₂, -L-Y, or labeled derivative thereof; or R^1 and said α -carboxylate, when taken together, form a lactone having 4 to 7 ring atoms;

each R^x is independently (C_1-C_{20}) alkylenyl;

R^y is (C_1-C_6) alkyl, (C_5-C_{50}) aryl (C_1-C_6) alkyl, (C_5-C_{50}) aryloxy (C_1-C_6) alkyl, hydroxyl, (C_1-C_6) alkoxy, (C_3-C_8) cycloalkyl, $N(R^3)_2$, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; heterocyclyl, (C_5-C_{50}) aryl (C_1-C_6) alkyl, or (C_3-C_{50}) heteroaryl (C_1-C_6) alkyl;

R^z is (C_1-C_6) alkyl, (C_3-C_8) cycloalkyl, $-R^x-O-(C_1-C_6)$ alkyl, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; (C_5-C_{50}) aryl (C_1-C_6) alkyl, or (C_3-C_{50}) heteroaryl (C_1-C_6) alkyl;

R^3 is, independently, H, (C_1-C_6) alkyl, or (C_1-C_6) alkyl- $N(R^4)_2$;

R^4 is, independently, H or (C_1-C_6) alkyl;

R^5 is $-C(=O)-(C_1-C_6)$ alkyl, $-C(=O)-(C_5-C_{50})$ aryl, $-SO_2-(C_5-C_{50})$ aryl, $-C(=O)NR^3R^4$, $-C(=O)-NR^4(C_5-C_{50})$ aryl, or $-C(=O)$ -heterocycle;

or R^3 and R^5 together form a (C_2-C_{10}) heterocycloalkyl;

L is an aliphatic or aromatic linkage; and

Y is a residue of an imageable moiety, peptide, peptidomimetic, or carbohydrate.

[0089] In certain more particular embodiments,

R^1 is (C_1-C_{20}) alkyl, hydroxy (C_1-C_{20}) alkyl, hydroxy (C_2-C_{20}) alkenyl, (C_2-C_{20}) alkenyl, (C_2-C_{20}) alkynyl, halo, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; (C_5-C_{50}) aryl (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroaryl (C_1-C_{20}) alkyl, (C_5-C_{50}) aryloxy (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroaryloxy (C_1-C_{20}) alkyl, (C_5-C_{50}) arylamino (C_1-C_{20}) alkyl, heteroarylamino (C_1-C_{20}) alkyl, amino (C_1-C_{20}) alkyl, $-R^x$ -

$C(=O)-R^y$, $-R^x-C(=O)-O-R^y$, $-R^x-O-R^z$, $-R^x-O-R^x-NR^3R^5$, $-L-Y$, or labeled derivative thereof; or R^1 and said α -carboxylate, when taken together, form a lactone having 4 to 7 ring atoms;

each R^x is independently (C_1-C_6) alkylenyl;

R^y is (C_1-C_6) alkyl, (C_3-C_8) cycloalkyl, $N(R^3)_2$, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; (C_5-C_{50}) aryl (C_1-C_6) alkyl, or (C_3-C_{50}) heteroaryl (C_1-C_6) alkyl;

R^z is (C_1-C_6) alkyl, (C_3-C_8) cycloalkyl, (C_5-C_{50}) aryl, (C_3-C_{50}) heteroaryl having at least one heteroatom selected from N, O, and S; (C_5-C_{50}) aryl (C_1-C_6) alkyl, or (C_3-C_{50}) heteroaryl (C_1-C_6) alkyl;

R^3 is, independently, H or (C_1-C_6) alkyl;

L is an aliphatic or aromatic linkage;

Y is a residue of an imageable moiety, peptide, peptidomimetic, or carbohydrate.

[0090] In certain other embodiments,

R^1 is (C_1-C_{20}) alkyl, hydroxy (C_1-C_{20}) alkyl, (C_2-C_{20}) alkenyl, (C_5-C_{50}) aryl, (C_5-C_{50}) aryl (C_1-C_{20}) alkyl, (C_3-C_{50}) heteroaryl (C_1-C_{20}) alkyl, (C_5-C_{50}) aryloxy (C_1-C_{20}) alkyl, amino (C_1-C_{20}) alkyl, $-R^x-C(=O)-R^y$, $-R^x-C(=O)-O-R^y$, $-R^x-O-R^z$, $-R^x-O-R^x-NR^3R^5$, $-R^x-NR^3R^5$, $-R^x-O-C(=O)-R^y$, (C_1-C_6) alkyl-B-(OH)₂, $-L-Y$, or labeled derivative thereof; or R^1 and said α -carboxylate, when taken together, form a lactone having 4 to 7 ring atoms.

[0091] The foregoing R^1 groups may be unsubstituted or substituted by one or more R^a groups as defined hereinabove (e.g., one or more hydrogen atoms have been replaced with an R^a group).

[0092] In yet other certain embodiments,

R^x is (C_1-C_6) alkylenyl.

[0093] In still yet other certain embodiments,

R^y is hydroxyl, (C_1-C_6) alkoxy, $N(R^3)_2$, or heterocyclyl.

[0094] In still yet other certain embodiments,

R^z is $-R^x-O-(C_1-C_6)$ alkyl.

[0095] In still yet other certain embodiments,

R^4 is, independently, H or (C_1-C_4) alkyl;

[0096] In still yet other certain embodiments,

R^5 is $-C(=O)-(C_1-C_6)alkyl$, $-C(=O)-(C_5-C_{10})aryl$, $-SO_2-(C_5-C_{10})aryl$, $-C(=O)NR^3R^4$, $-C(=O)-NR^4(C_5-C_{10})aryl$, or $-C(=O)-heterocycle$.

[0097] In certain preferred embodiments of the compounds of the invention, R^1 preferably comprising an $-(CH_2)_x-$ group, where x is an integer from 1 to 3, preferably 1, adjacent to the α -carbon atom, so that there is no substantial steric bulk immediately adjacent to the stereocenter of the amino acid.

[0098] In certain preferred embodiments of the compounds of the invention, R^1 is a hydroxy(C_1-C_{20})alkyl, preferably hydroxy(C_1-C_6)alkyl, more preferably hydroxy(C_1-C_4)alkyl.

[0099] In certain preferred embodiments of the compounds of the invention, R^1 is a hydroxy(C_2-C_{20})alkenyl, preferably hydroxy(C_2-C_6)alkenyl, more preferably hydroxy(C_2-C_4)alkenyl.

[00100] In certain preferred embodiments, the compounds of the invention are selected from the group consisting of:

- 2-Amino-2-benzyl-6-boronohexanoic acid;
- 2-Allyl-2-amino-6-boronohexanoic acid;
- 2-Amino-2-(4-boronobutyl)succinic acid;
- 2-Amino-6-(borono-2-(3-phenoxypropyl)hexanoic acid;
- 2-Amino-6-borono-2-(4-phenylbutyl)hexanoic acid;
- 2-Amino-6-borono-2-(3-(4-chlorophenoxy)propyl)hexanoic acid;
- 2-Amino-6-borono-2-(3-(4-methoxyphenoxy)propyl)hexanoic acid;
- 2-Amino-6-borono-2-(3-(4-fluorophenoxy)propyl)hexanoic acid;
- 2-Amino-6-borono-2-(3-(4-nitrophenoxy)propyl)hexanoic acid;
- 2-Amino-2-(3-(benzo[*d*][1,3]dioxol-5-yloxy)propyl)-6-boronohexanoic acid;
- 2-Amino-6-borono-2-(3-(4-(trifluoromethyl)phenoxy)propyl)hexanoic acid;
- 2-Amino-6-borono-2-(3-(3-methoxyphenoxy)propyl)hexanoic acid;
- 2-Amino-6-borono-2-(3-(3-phenoxyphenoxy)propyl)hexanoic acid;
- 2-Amino-6-borono-2-(3-(3-isopropylphenoxy)propyl)hexanoic acid;
- 2-Amino-2-(3-(biphenyl-4-yloxy)propyl)-6-boronohexanoic acid;
- 2-Amino-2-(3-(biphenyl-3-yloxy)propyl)-6-boronohexanoic acid;

2-Amino-6-borono-2-(3-(3-(trifluoromethyl)phenoxy)propyl)hexanoic acid;
 2-Amino-6-borono-2-(3-(4-(trifluoromethylthio)phenoxy)propyl)hexanoic acid;
 2-Amino-6-borono-2-(3-(2,6-difluorophenoxy)propyl)hexanoic acid;
 2-Amino-6-borono-2-(3-(*o*-tolylloxy)propyl)hexanoic acid;
 2-Amino-6-borono-2-(3-(*p*-tolylloxy)propyl)hexanoic acid;
 4-(4-Amino-8-borono-4 carboxyoctyloxy)benzoic acid;
 2-Amino-2-(3-(4-aminophenoxypropyl)-6-boronohexanoic acid;
 2-Amino-6-(borono-2-(pyridin-3-ylmethyl)hexanoic acid;
 2-Amino-2-(benzyloxyethyl)-6-boronohexanoic acid;
 2-Amino-6-borono-2-(2-methoxyethyl)hexanoic acid;
 2-Amino-6-borono-2-(2-(*p*-tolyoxy)ethyl)hexanoic acid;
 2-Amino-6-borono-2-(2-(3-chlorophenoxy)ethyl)hexanoic acid;
 2-Amino-6-borono-2-(2-(2,3-dihydrobenzo[*b*][1,4]dioxin-5-yloxy)ethyl)hexanoic acid;
 2-Amino-6-borono-2-((2,3-dihydrobenzo[*b*][1,4]dioxin-2-yl)methyl)hexanoic acid;
 2-Amino-6-borono-2-(2-(3-methoxyphenoxy)ethyl)hexanoic acid;
 2-Amino-6-borono-2-(2-(3-nitrophenoxy)ethyl)hexanoic acid;
 2-Amino-6-borono-2-(2-(3-(morpholinosulfonyl)phenoxy)ethyl)hexanoic acid;
 2-Amino-2-(2-(3-aminophenoxy)ethyl)-6-boronohexanoic acid;
 2-Amino-6-borono-2-(3-hydroxypropyl)hexanoic acid;
 2-Amino-6-borono-2-(4-boronobutyl)hexanoic acid;
 2-Amino-2-(4-boronobutyl)hex-4-enoic acid;
 2-Amino-6-borono-2-(2-(2-methoxyethoxy)ethyl)hexanoic acid;
 2-Amino-6-borono-2-methylhexanoic acid;
 2-Amino-6-borono-2-isobutylhexanoic acid;
 2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid;
 (*R*)-2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid;
 (*S*)-2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid;
 2-Amino-2-(2-(benzyloxy)-2-oxoethyl)-6-boronohexanoic acid;
 2-Amino-6-borono-2-(2-methoxy-2-oxoethyl)hexanoic acid;
 2-Amino-6-borono-2-(cyanomethyl)hexanoic acid;
 2-Amino-6-borono-2-(2-oxobutyl)hexanoic acid;

2-Amino-6-borono-2-(2-oxo-2-phenylethyl)hexanoic acid;
 2-Amino-2-(2-(2-aminoethoxy)ethyl)-6-boronohexanoic acid;
 2-Amino-6-borono-2-(3-(piperidin-4-yl)propyl)hexanoic acid;
 2-Amino-6-borono-2-(3-(piperazine-1-yl)propyl)hexanoic acid;
 2,6-Diamino-2-(4-boronobutyl)hexanoic acid;
 2-Amino-6-borono-2-(2-(2-(4-cyanobenzamid)ethoxy)ethyl)hexanoic acid;
 2-(2-(2-Acetamidoethoxy)ethyl)-2-amino-6-boronohexanoic acid;
 2-Amino-6-borono-2-(2-(2-(3-(3-methoxyphenyl)ureido)ethoxy)ethyl)hexanoic acid;
 2-(3-(1-Acetylpiperidin-4-yl)propyl)-2-amino-6-boronohexanoic acid;
 2-Amino-6-borono-2-(3-(1-(3-methoxyphenylcarbamoyl)piperidin-4-yl)propyl)hexanoic acid;
 2-(3-(4-Acetylpiperazin-1-yl)propyl)-2-amino-6-boronohexanoic acid;
 2-Amino-6-borono-2-(3-(4-(4-cyanobenzoyl)piperazine-1-yl)propyl)hexanoic acid;
 2-Amino-6-borono-2-(3-(4-(3-methoxyphenylcarbamoyl)piperazin-1-yl)propyl)hexanoic acid;
 2-Amino-6-borono-2-(4-(4-methylphenylsulfonamido)butyl)hexanoic acid;
 2-Amino-6-borono-2-(4-(3,5-difluorobenzamido)butyl)hexanoic acid;
 2-Amino-6-(benzyloxycarbonylamino)-2-(4-boronobutyl)hexanoic acid;
 6-Acetamido-2-amino-2-(4-boronobutyl)hexanoic acid;
 2-amino-6-borono-2-(4-(3-(3-methoxyphenyl)ureido)butyl)hexanoic acid;
 2-Amino-4-(2-hydroxyguanidino)-2-methylbutanoic acid; and
 pharmaceutically acceptable salts thereof. Examples of pharmaceutically acceptable salts include addition salts of hydrochloric and trifluoroacetic acid.

[00101] The L-stereoisomers of the foregoing compounds are preferred embodiments of this invention. More particularly, the preferred embodiments of this invention include those compounds analogous (*S*)-ABH or (*S*)-norNOHA (see Scheme 18), in which the (*R*)-proton has been stereospecificly replaced with an R¹ group as described herein. These specific derivatives possess the most potency for the inhibition of arginase (lower K_i values, see Example 69, below). Molecular docking of both enantiomers into the crystal structure of arginase indicated that the stereospecific replacement of the (*R*)-H group resulted in a compound where the boronobutyl side chain can bind near the dimanganese ions in the active site of the enzyme without disruption

of important active-site interactions. The products of the stereospecific replacement of the (*R*)-H group, however, can be described as either having *R*- or *S*-stereochemical configuration, depending on the convention for the prioritization of the four substituents on the α -carbon. As an example, the preferred embodiment of compound **1ao** (see Example 41, below) is an *S*-product due to the methyl group having the lowest priority. On the other hand, the preferred embodiment of compound **1d** (see Example 4, below) is an *R*-product due to the higher priority of the phenoxypropyl side chain than the boronobutyl side chain on the α -carbon.

[00102] In addition to data from molecular docking studies, laboratory data for the single enantiomers **1ar** and **1as** (see Examples 44, 45, and 69, below) illustrate the importance of the stereochemistry. A racemic intermediate in the synthesis of compounds **1ar** and **1as** was resolved by chiral chromatography into single enantiomeric compounds **47a** and **47b**. The later eluting peak was assigned the *R*-configuration for the compound based on literature precedent where absolute stereochemistry was proven. See, Lee et al., Org Lett. 7, 1557-60 (2005); Jew et al., Agnew. Chem. Int. Ed. 43, 2382-85 (2004). Each of the single enantiomeric compounds **47a** and **47b** were converted to final single enantiomeric compounds **1ar** and **1as**, respectively by unambiguous chemistry. Final compounds **1ar** and **1as** were tested for arginase inhibition. The enantiomer with the proposed *R*-configuration, compound **1ar**, possessed the most potency as an arginase inhibitor by two orders of magnitude compared to compound **1as**. These biological data were consistent with the molecular docking for the preferred embodiments.

[00103] In certain preferred embodiments of compounds of the invention, X^2 is -S- or -O-.

[00104] In certain preferred embodiments of compounds of the invention, X^2 is -S-.

[00105] In certain preferred embodiments of compounds of the invention, X^2 is -O-.

[00106] In certain preferred embodiments of compounds of the invention, X^2 is -(NR²)-

[00107] In certain preferred embodiments of compounds of the invention, X^3 is -S-.

[00108] In certain preferred embodiments of compounds of the invention, X^3 is -O-.

[00109] In certain preferred embodiments of compounds of the invention, X^3 is -(NR²)-

- [00110] In certain preferred embodiments of compounds of the invention, R^2 is H.
- [00111] In certain preferred embodiments of compounds of the invention, R^2 is methyl.
- [00112] In certain preferred embodiments of compounds of the invention, R^2 is ethyl.
- [00113] In certain preferred embodiments of compounds of the invention, R^3 is, independently, H, methyl, or ethyl.
- [00114] In certain preferred embodiments of compounds of the invention, R^3 is H.
- [00115] In certain preferred embodiments of compounds of the invention, R^3 is methyl.
- [00116] In certain preferred embodiments of compounds of the invention, R^3 is ethyl.


Prodrugs of Arginase Inhibitors

[00117] In certain preferred embodiments of the compounds of the invention, R^1 and the α -carboxylate, when taken together, form a lactone having 4 to 7 ring atoms, preferably a 4- to 7-membered ring lactone. The lactone would undergo hydrolysis *in vivo* to release the active form of the arginase inhibitor. For example, the HMG-CoA reductase inhibitor lovastatin contains a 6-membered ring lactone that undergoes hydrolysis at gastric pH and temperature (half-life of about 1 hour) to form the pharmacologically active hydroxy acid. See, e.g., Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology, Testa and Mayer, Eds. Wiley Interscience (2003). Thus, a lactone form is essentially a prodrug form of a compound of the invention.


[00118] In certain embodiments of the compounds of the invention, R^1 may be a hydroxyalkenyl and, together with the α -carboxylate, can form a cyclic lactone, preferably 6- and 7-membered rings, and the double bond can be part of an aromatic ring, as shown below in Schemes 1-2 (which illustrate some exemplary arginase inhibitors in prodrug form according to certain exemplary embodiments hereof). The aromatic ring can be otherwise unsubstituted ($M = H$), or it can be substituted with electron donating groups such as $-NH_2$ or $-CH_3$, or with electron-withdrawing groups such as $-NO_2$ or $-Cl$, to alter the stability of the ester linkage of the lactone

for hydrolysis *in vivo*. This substitution can be made at any position on the aromatic ring; substitutions at *ortho* or *para* positions relative to the phenolic oxygen would allow for direct resonance effects with certain M groups (e.g., -NH₂ or -NO₂) to modulate the reactivity of the ester linkage. In the case of the 6-membered ring, with M = H, the skeleton of the bicyclic ring system is that of dihydrocoumarin. Unsubstituted dihydrocoumarin has a half-life of about 1 hour at 37°C in the stomach, so the hydrolysis of the dihydrocoumarin *in vivo* will release the active form of the arginase inhibitor on a therapeutically-relevant timescale. Preparation of 3-substituted and 3,3-disubstituted dihydrocoumarin derivatives may be prepared by conventional techniques, such as those disclosed in Murakata et al., Chem. Pharm. Bull 47, 1380-83 (1999). The cyclic lactone prodrugs may also be prepared in accordance with the general syntheses described in US Pat. No. 3,161,655 (December 15, 1964), such as Example 11 thereof.

Scheme 1



Scheme 2



Pharmaceutical Compositions of Arginase Inhibitors

[00119] In certain embodiments, the invention is directed to compositions, comprising:
at least one compound of the invention or a pharmaceutically acceptable salt thereof; and
a pharmaceutically-acceptable carrier.

[00120] In other embodiments, the invention is directed to pharmaceutical compositions,
comprising:

- at least compound of the invention or pharmaceutically acceptable salt thereof; and
- at least one pharmaceutically acceptable carrier.

Generally, the compound or pharmaceutically acceptable salt thereof will be present in an effective amount. Generally, the compound or a pharmaceutically acceptable salt thereof will be present at a level of from about 0.1%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition. Preferably, the compound or a pharmaceutically acceptable salt thereof will be present at a level of at least about 1%, by weight, based on the total weight of the pharmaceutical composition. More preferably, the compound or a

pharmaceutically acceptable salt thereof will be present at a level of at least about 5%, by weight, based on the total weight of the pharmaceutical composition. Even more preferably, the compound or a pharmaceutically acceptable salt thereof will be present at a level of at least about 10%, by weight, based on the total weight of the pharmaceutical composition. Yet even more preferably, the compound or a pharmaceutically acceptable salt thereof will be present at a level of at least about 25%, by weight, based on the total weight of the pharmaceutical composition.

[00121] Embodiments of the invention also include combination therapies, which include coadministration of an arginase inhibitor hereof with another medicine. More particularly, the term “combination therapy” refers to the administration of two or more therapeutic agents or compounds to treat a therapeutic condition or disorder described in the present disclosure. Such administration includes use of each type of therapeutic agent in a concurrent or simultaneous manner. Such administration includes the use of each type of therapeutic agent in the same unit dosage form or in separate unit dosage forms. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

[00122] Accordingly, in certain embodiments, the invention is directed to compositions, comprising:

- a compound of the invention or a pharmaceutically acceptable salt thereof;
- a phosphodiesterase-1 (PDE1) inhibitor, a phosphodiesterase-2 (PDE2) inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, or a non-specific PDE inhibitor that inhibits PDE1, PDE2, PDE5, or a combination thereof; and
- optional pharmaceutically-acceptable excipient.

The arginase inhibitors of the invention are useful in the treatment of patients who do not respond to PDE5 inhibitors because arginase operates at an earlier stage in the pathway leading to NO-dependent relaxation of genital smooth muscle tissue required for sexual arousal.

[00123] Suitable phosphodiesterase-1 (PDE1) inhibitors include 5E3623 (available from Eisai), BAY 383045 (available from Bayer), HFV 1017 (7-benzenesulfonylamino-3a-ethyl-1,2,3,3a,10,11b-hexahydro-11H-5a,11a-diaza-benzo[cd]fluoranthene-5-carboxylic acid ethyl ester 2,3-dihydroxy-succinate available from Daiichi Fine Chemical), KF 19514 (5-phenyl-

3-(3-pyridil) methyl-3H-imidazo[4,5-c][1,8] naphthyridin-4(5H)-one available from Kyowa Hakko) and SCH 51866 ((cis-5,6a,7,8,9,9a-hexahydro-2-[4-(trifluoromethyl)phenylmethyl]-5-methyl-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one) available from Schering-Plough).

[00124] Suitable phosphodiesterase-2 (PDE2) inhibitors include BAY 607550 (2-(3,4-Dimethoxy-benzyl)-7-[1-(1-hydroxy-ethyl)-4-phenyl-butyl]-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one available from Bayer).

[00125] Suitable phosphodiesterase-5 (PDE5) inhibitors include sildenafil (sold under the tradename Viagra™), vardenafil (sold under the tradename Levitra™), tadalafil (sold under the tradename Cialis™), mirodenafil, udenafil, avanafil, dasantafil, NM 702 (4-bromo-6-[3-(4-chloro-phenyl)-propoxy]-5-[(pyridin-3-ylmethyl)-amino]-2H-pyridazin-3-one hydrochloride available from Nissan Chemical Industries), SLx-2101 (available for Surface Logix) and UK 369003 (available from Pfizer).

[00126] Suitable non-specific PDE inhibitors that inhibit PDE1, PDE2, PDE5, or a combination thereof include amlexanox, caffeine citrate, doxofylline, levosimendan, mopidamol, pentoxifylline, pemobendan, propentofylline, vesnarinone, and ibudilast.

[00127] Such compositions are prepared in accordance with acceptable pharmaceutical procedures, such as described in *Remington's Pharmaceutical Sciences*, 17th edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, PA (1985). Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable.

[00128] In certain embodiments, compounds of the invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances that may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid that is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably

contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes, and ion exchange resins.

[00129] Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups, and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

[00130] Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be administered by, for example, intramuscular, intraperitoneal, or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

[00131] Preferably, the pharmaceutical composition is in unit dosage form, e.g., as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

[00132] In another embodiment of the present invention, the compounds useful in the present invention may be coadministered to a mammal with one or more other pharmaceutical active agents such as those agents being used to treat any other medical condition present in the mammal. Examples of such pharmaceutical active agents useful for such combination therapies include pain relieving agents, anti-angiogenic agents, anti-neoplastic agents, anti-diabetic agents, anti-infective agents, or gastrointestinal agents, or combinations thereof.

[00133] The one or more other pharmaceutical active agents may be administered in a therapeutically effective amount simultaneously (such as individually at the same time, or together in a pharmaceutical composition), or successively with one or more compounds of the present invention.

[00134] The route of administration may be any route, which effectively transports the active compound of the invention to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal, such as passive or iontophoretic delivery, or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment. Furthermore, the administration of compound of formula Ia or formula Ib with other active ingredients may be concurrent or simultaneous.

[00135] It is especially advantageous to formulate the compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrete units suited as unitary dosages for the patient to be treated; each unit containing a predetermined quantity of the peptide calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of the patients.

[00136] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[00137] Typically, dosages of the compounds of the invention that can be administered to an animal, preferably a human, range in amount from 1 microgram to about 100 milligrams per

kilogram of body weight of the animal. The precise dosage administered will vary depending upon any number of factors, including but not limited to, the type of animal and type of disorder being treated, the age of the animal and the route of administration. Preferably, the dosage of the compound will vary from about 10 micrograms to about 10 milligrams per kilogram of body weight of the animal. More preferably, the dosage will vary from about 100 micrograms to about 5 milligrams per kilogram of body weight of the animal.

[00138] Typically, the compounds of the invention can be administered to an animal as frequently as several times daily, or it can be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every several months or even once a year or less. The frequency of the dose will be readily apparent to the skilled artisan and will depend upon any number of factors, such as, but not limited to, the type and severity of the disorder being treated, the type and age of the animal, etc.

Diagnostic Uses of Arginase Inhibitors

[00139] Diagnostic medical imaging has become a critical element of modern health care. Ultrasound, radionuclide, X-ray, and magnetic resonance imaging techniques facilitate the diagnosis of disease. Diagnostic pharmaceuticals, frequently called contrast agents, may be administered to a patient in place of a therapeutic arginase inhibitors, or they may be simultaneously administered with a therapeutic agent to a patient to augment the usefulness of the imaging technique itself. Such imaging agents act by altering the energy or the way that energy interacts with tissues. Diagnostic medical imaging frequently uses targeted contrast agents that, in binding or localizing at sites selectively within the body, help to resolve an image of diagnostic interest.

[00140] Targeted diagnostic imaging contrast agents generally consist of a targeting moiety labeled with a traceable imaging moiety. Such traceable imaging moieties include fluorescent tags; radio-opaque dyes (e.g., iodinated aromatics), radioactive elements such as ^3H , ^{18}F , ^{125}I , ^{129}I ; or diagnostically useful chelated radioactive or paramagnetic metals such as Gd(III), Mn(II), Tc-99m, Re-186, Re-188, In-111, or Ga-67. Examples of useful diagnostic imaging agents of the invention include compounds according to formulas IA, IB, Ia, and Ib,

wherein at least one hydrogen atom of the R^1 group has been substituted with one of the foregoing imaging moieties.

[00141] The targeting moiety carries the label to the site of diagnostic interest where it is detected, e.g., by MRI, US, CT, or radionuclide imaging (including SPECT and PET). In certain preferred embodiments of compounds of formula IA or formula IB, Y is a residue of an imageable moiety selected from the group consisting of a gamma ray emitting radioisotope, a positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

[00142] By using such an arginase inhibitor suitable conjugated to an imageable moiety, endogenous arginase activity may be visually observed in a patient's body in real time. In order to be effective, the imageable moiety should not significantly interfere with the binding of the derivatized arginase inhibitor to its substrate. For example, arginase-inhibitor imageable-moiety conjugate will generally have a K_i or less than about 1000 nM.

[00143] In certain preferred embodiments of compounds of formula IA or formula IB, R^1 is a fluorescently-labeled derivative thereof.

[00144] In certain embodiments of the invention, a spectroscopic probe, such as a fluorescent moiety or an NMR or MRI sensitive moiety or complex is covalently attached as the R^1 group through a flexible linker sufficiently long so that the probe does not make unfavorable interactions with the protein surface. Such spectroscopic probe would be a useful diagnostic tool for noninvasive determination of arginase overexpression, as observed in certain disease states, such as, for example, asthma (overexpression of airway arginase), cancer (overexpression of arginase in certain breast cancers, colon cancers, and the like), or certain internal bacterial infections (e.g., *H. pylori* overexpresses bacterial arginase in order to evade the immune response in human stomach ulcers).

[00145] In other embodiments, the invention is directed to methods of diagnosing arginase overexpression in a patient, comprising the step of:

administering to said patient a diagnostically-effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof;

where R^1 is a labeled derivative thereof; and
 imaging said patient.

In certain preferred embodiments, the arginase overexpression is associated with asthma, cancer, bacterial infections, or combinations thereof.

[00146] In other aspects, the invention is directed to methods of diagnosing arginase overexpression in a patient, comprising the step of:

administering to said patient a diagnostically-effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof;

where Y is an imageable moiety; and
 imaging said patient.

In certain preferred embodiments, the arginase overexpression is associated with asthma, cancer, bacterial infections, or combinations thereof.

[00147] In certain aspects, the invention is directed to methods for radioimaging a patient, comprising the steps of:

administering to said patient an effective amount of a compound of the invention;
 wherein Y is an imageable moiety; and
 scanning said patient using a radioimaging device.

[00148] In certain aspects, the invention is directed to methods of inhibiting arginase, comprising the step of:

contacting said arginase with a compound of the invention or a salt thereof.

In certain embodiments, the arginase is yeast, bacterial, parasitic, or mammalian. In certain other embodiments, mammalian arginase is a human type I arginase or a human type II arginase (e.g., human penile arginase).

[00149] In certain aspects, the invention is directed to diagnostic compositions, comprising:

a diagnostically-effective amount of the compound of the invention or a pharmaceutically acceptable salt thereof; and
 a pharmaceutically acceptable carrier;
 where R^1 is a labeled derivative thereof.

[00150] In certain aspects, the invention is directed to diagnostic compositions, comprising:

a diagnostically-effective amount of the compound of the invention or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier;

where Y is an imageable moiety.

Therapeutic Uses of Arginase Inhibitors

[00151] The invention is based upon the discovery of compounds that inhibit the enzymatic activity of arginase. These compounds, which were not previously known to inhibit this enzyme (and not previously known to have any use), are useful for a variety of applications in medicine and research.

[00152] The compounds, compositions, and methods of the invention are useful for inhibiting the activity of arginase including, but not limited to, mammalian (e.g., human), yeast, and bacteria (such as *H. pylori*) arginase. The compounds, compositions, and methods described herein can be used to inhibit arginase activity *in vitro* or *in vivo*, for example, in a human. These compositions can also be used to treat a disorder characterized either by abnormally high arginase activity in a tissue of a mammal or by abnormally low nitric oxide synthase activity in a tissue of the mammal, preferably a human. “Inhibition” of arginase by an arginase inhibitor, as used herein, means reduction in the level of arginase activity in the presence of the inhibitor, compared with the level of arginase activity in the absence of the inhibitor.

[00153] There are a large number of arginase-linked diseases, some of which are listed below. They are linked with the one, two, or all of the three phenomena related to constitutive or upregulated arginase activity described above. Many of these diseases are characterized by two or even three of the phenomena simultaneously or sequentially, e.g., cellular proliferation and accumulation of fibrotic tissue can stiffen airway or vascular tissue in a constricted state so that it is more difficult to achieve NO-dependent relaxation. Accordingly, the compounds of the invention may be used to treat conditions associated with abnormally high level of arginase activity or abnormally low level of NO synthase activity. An “abnormally high level of arginase

activity,” as used herein, means a level of arginase activity that exceeds the level found in normal tissue when the normal tissue does not exhibit an arginase related disorder phenotype. An “abnormally low level of NO synthase activity,” as used herein, means a level of NO synthase activity which is lower than that found in normal tissue when the normal tissue does not exhibit an NO synthase related disorder phenotype.

[00154] For example, the arginase inhibitors disclosed herein may be useful in the treatment, prevention, management, or diagnosis of one or more of the following diseases, conditions, or maladies, each of which is discussed individually below: (1) gastrointestinal diseases, (2) pulmonary inflammatory diseases, (3) sexual arousal disorders, (4) cardiovascular disorders, (5) diseases caused by a pathogenic microorganisms, (6) immunological disorders, (7) cancer, (8) pre-term labor, (9) Reynaud’s disease, (10) psoriasis, (11) rheumatoid arthritis, and (12) Peyronie’s Disease, among others. Each of these conditions is discussed below.

1. Gastrointestinal Diseases

[00155] An increase in arginase activity has been associated with the pathophysiology of a number of conditions including impairment in non-adrenergic and non-cholinergic (NANC) nerve-mediated relaxation of gastrointestinal smooth muscle. An arginase inhibitor can be used to alleviate such impairment by administering the inhibitor to a mammal experiencing such impairment or a mammal which is anticipated to experience such impairment (e.g., a human afflicted with a gastrointestinal motility disorder).

[00156] Accordingly, the compounds of the invention may be useful in the treatment or prevention of gastrointestinal motility disorders, which is based on the observation that arginase is present in opossum internal anal sphincter muscle and the known arginase inhibitor, ABH, has been shown to relax this muscle. See, e.g., Baggio et al., J. Pharm. Exp. Ther. 290, 1409-16 (1999).

[00157] The compounds of the invention may also be useful in the treatment or prevention of inflammatory bowel disease (e.g., Crohn’s disease and ulcerative colitis). In fact, IBD has been shown to be characterized by increased arginase activity and endothelial dysfunction. See, e.g., Horowitz et al., Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1323-36 (2007).

[00158] Likewise, the compounds of the invention may be useful in the treatment or prevention of gastric ulcers, because the bacterium that causes stomach ulcers, *Helicobacter pylori*, exhibits increased arginase activity upon colonization in order to evade the human immune response. See, e.g., Gobert et al., Proc. Natl. Acad. Sci. (USA) 98, 13844-49 (2001).

2. Pulmonary Inflammatory Diseases

[00159] The compounds of the invention may be useful in the treatment or prevention of asthma based on the observation that arginase is upregulated in the asthmatic airway. See, e.g., Zimmermann and Rothenberg, Eur. J. Pharmacol. 533, 253-62 (2006). Furthermore, nebulizer treatment of guinea pigs with ABH in an allergic asthma model prevents airway hyperresponsiveness. See, e.g., Maarsingh, "Arginase: A Novel Key Enzyme in the Pathophysiology of Allergic Asthma," Ph.D. dissertation, Chapter 9, University of Groningen, Netherlands (2006); Maarsingh et al., Am. J. Respir. Crit. Care Med. 178, 565-73 (2008). The asthma phenotype is characterized by airway constriction, airway smooth muscle hyperplasia, and the chronic accumulation of fibrotic tissue; an arginase inhibitor can relax airway smooth muscle and attenuate cellular hyperplasia and fibrosis.

[00160] Additionally, the compounds of the invention may be useful in the treatment or prevention of chemically-induced lung fibrosis because arginase I and II are induced in bleomycin-induced lung fibrosis in order to provide more L-ornithine for collagen biosynthesis. See, e.g., Endo et al., Am. J. Physiol. Lung Cell Mol. Physiol. 285, L313-21 (2003).

[00161] The compounds of the invention may also be useful in the treatment or prevention of idiopathic pulmonary fibrosis, based on the observation that virus-induced upregulation of arginase I is observed in an animal model. See, e.g., Mora et al., Am. J. Respir. Cell Mol. Biol. 35, 466-73 (2006).

[00162] Furthermore, the compounds of the invention may be useful in the treatment or prevention of cystic fibrosis. Increased sputum arginase activity contributes to NO deficiency in cystic fibrosis lung disease; arginase activity also contributes to fibrosis. See, e.g., Graseman et al., Am. J. Respir. Crit. Care Med. 172, 1523-28 (2005).

3. Sexual Arousal Disorders

[00163] Erectile dysfunction afflicts one-half of the male population over the age of forty. This malady often results from defects in the complex cascade of enzyme-catalyzed reactions governing blood flow into and out of the corpus cavernosum, a chamber of muscular, spongy tissue that becomes engorged with blood in the erect penis. Defects that compromise cavernosal blood flow often occur as secondary complications related to other health conditions, such as heart disease, hypertension, diabetes, use of certain medications, and the like.

[00164] In an important embodiment, the invention relates to use of an arginase inhibitor described herein for enhancing penile erectile function in a mammal (preferably a male human) or for alleviating erectile dysfunction in a mammal. NO is an important regulator of erectile function and mediates NANC neurotransmission in penile corpus cavernosum smooth muscle, leading to rapid relaxation, which in turn leads to erection. NO synthase, which catalyzes oxidation of L-arginine to form L-citrulline and NO, is for this reason a key enzyme in penile smooth muscle physiology. Arginase catalyzes hydrolysis of L-arginine to form L-ornithine and urea. Arginase regulates NO synthase activity by affecting the amount of L-arginine available for oxidation catalyzed by NO synthase activity. Thus, inhibition of arginase activity can enhance NO synthase activity, thereby enhancing NO-dependent smooth muscle relaxation in the corpus cavernosum and enhancing penile erection.

[00165] Arginase is present in rabbit and human penile corpus cavernosum and ABH enhances the NO-dependent relaxation of this tissue. See, e.g., Cox et al., *Nature Struct. Biol.* 6, 1043-47 (1999). The arginase inhibitor, ABH, enhances the erectile response in live male rabbits. See, e.g., Cama et al., *Biochemistry* 42, 8445-51 (2003). Arginase II is upregulated in the corpus cavernosum of the diabetic man, resulting in reduced NO biosynthesis which, in turn, leads to erectile dysfunction; administration of ABH in *ex vivo* experiments restores NO biosynthesis. See, e.g., Bivalacqua et al., *Biochem. Biophys. Res. Commun.* 283, 923-27 (2001). Arginase I is upregulated in the penis of aged mice and impairs erectile function. See, e.g., Bivalacqua et al., *Am. J. Physiol. Heart Circ. Physiol.* 292, H1340-51 (2007).

[00166] The compounds of the invention may also be useful in the treatment or prevention of female sexual arousal disorder. The arginase inhibitor, ABH, enhances the engorgement

response in the genitalia of live female rabbits. See, e.g., Cama et al., *Biochemistry* 42, 8445-51 (2003).

4. Cardiovascular Disorders

[00167] The compounds of the invention may be useful in the treatment or prevention of endothelial vascular dysfunction in atherosclerosis, hypertension, hypercholesterolemia, and diabetes. Arginase modulates NOS activity by regulation of L-arginine availability, and the deleterious effects of arginase can be blocked by an arginase inhibitor. See, e.g., Berkowitz et al., *Circulation* 108, 2000-06 (2003); Yang and Ming, *Clin. Med. Res.* 4, 53-65 (2006). Increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing L-arginine availability to NO synthase. See, e.g., Romero et al., *Circ. Res.* 102, 95-102 (2008). Arginase inhibition attenuates hypertension in spontaneously hypertensive rats. See, e.g., Demougeot et al., *J. Hypertens.* 23, 971-78 (2005). Other relevant conditions include ischemia-reperfusion injury, peripheral vascular disease (PVD), peripheral arterial disease (PAD), and subarachnoid hemorrhage. Arginase has been identified as a new drug target for the treatment of atherosclerosis. See, e.g., Yang and Ming, *Curr. Hypertension Rep.* 8, 54-59 (2006).

[00168] The compounds of the invention may be useful in the treatment or prevention of pulmonary arterial hypertension. Elevated arginase activity contributes to vascular endothelial dysfunction by compromising L-arginine availability to NO synthase. See, e.g., Morris et al., *Adv. Pulmonary Hypertension* 5, 31-36 (2007).

5. Diseases Caused by Pathogenic Microorganisms

[00169] The compounds of the invention may be useful in the treatment or prevention of African sleeping sickness, Chagas' disease, leishmaniasis, malaria, and other diseases caused by pathogenic microorganisms. Polyamine biosynthetic enzymes are essential for growth and survival of protozoa. See, e.g., Heby et al., *Biochem. Soc. Trans.* 31, 415-19 (2003). Arginase is essential for viability. See, e.g., Roberts et al., *J. Biol. Chem.* 279, 23668-78 (2004). Therefore, inhibitors of protozoan arginases can kill the protozoa.

[00170] Additionally, certain bacteria hydrolyze D-arginine with an enzyme known as D-arginase, also known as guanidinobutyrase, Arakawa et al., J. Biochem. 133, 33-42 (2003), and the D-stereoisomers of the compounds of formula IA and IB are expected to be effective inhibitors of this hydrolysis. Further, the compounds of formula IA and IB would also be suitable as antibacterial agents because they are expected to exhibit antibacterial properties, e.g., against guanidinobutyrase of *Pseudomonas aeruginosa*. See, Nakada and Itoh, J. Bacteriol. 184, 3377-84 (2002).

[00171] Arginase can be inhibited in yeast by contacting the yeast with the composition of the invention. Inhibition of arginase in yeast serves to minimize urea production during fermentation of alcoholic beverages.

6. Immunological Disorders

[00172] The compounds of the invention may be useful in the treatment or prevention of multiple sclerosis, and possibly other autoimmune diseases, based upon the observation that arginase I is upregulated in an animal model of multiple sclerosis (experimental autoimmune encephalomyelitis) and administration of the arginase inhibitor ABH improves the disease score of animals. See, e.g., Xu et al., Immunology 110, 141-48 (2003).

7. Cancer

[00173] Tumor-induced tolerance impairs the therapeutic efficacy of immunotherapy; one mechanism leading to T-cell tolerance is the generation of myeloid-derived suppressor cells (MDSCs), which produce arginase, thereby depleting the tumor microenvironment of L-arginine, which impairs T-cell signal transduction and function. T-cell anergy results. Notably, arginase activity is a mechanism of immune system evasion that is also shared by certain bacteria, e.g., *Helicobacter pylori*. MDSCs are regarded as “cancer’s bulwark against immune attack.” See, e.g., Marx, Science 319, 154-56 (2008).

[00174] Accordingly, arginase is upregulated in the following types of cancers, which may be treated with an arginase inhibitor described herein: Renal cell carcinoma (see, e.g., Zea et al., Cancer Res. 65, 3044-48 (2005); Ochoa et al., Clin. Cancer Res. 13, 721s-26s (2007)); prostate

cancer (see, e.g., Bronte et al., J. Exp. Med. 201, 1257-68 (2005) (arginase inhibition with *N*-hydroxy-L-arginine facilitates tumor immunotherapy); colorectal cancer (see, e.g., Leu and Wang, Cancer 70, 733-36 (1992); Bronte and Zanovello, Nature Rev. Immunol. 5, 641-54 (2005)); breast cancer (see, e.g., Singh et al., Cancer Res. 60,3305-12 (2000); Bronte and Zanovello, Nature Rev. Immunol. 5, 641-54 (2005) (the arginase inhibitor, *N*-hydroxy-L-arginine, inhibits cell proliferation and induces apoptosis)); skin cancer (squamous cell and basal cell cancers) (see, e.g., Gokmen et al., J. Lab. Clin. Med. 137, 340-44 (2001); Bronte and Zanovello, Nature Rev. Immunol. 5, 641-54 (2005)); lung cancer (see, e.g., Rodriguez et al., J. Exp. Med. 202, 931-39 (2005); Bronte and Zanovello, Nature Rev. Immunol. 5, 641-54 (2005)); ovarian cancer (see, e.g., Melichar et al., J. Translational Med. 1, 1-5 (2003) (doi:10.11861479-5876-1-5)); and gastric cancer (see, e.g., Wu et al., Life Sci. 51, 1355-61 (1992)); among others.

8. Management of Pre-Term Labor

[00175] Enhancement of uterine smooth muscle relaxation with an arginase inhibitor may be useful in the management of pre-term labor.

9. Reynaud's Disease

[00176] Reynaud's disease is a disease of the microvasculature. Because subcutaneous administration of the arginase inhibitor BEC (which is an analogue of ABH) in humans is vasodilatory and enhances circulation, an arginase inhibitor may be useful in treating Reynaud's disease. See, e.g., Holowatz et al., J. Physiol. 574, 573-81 (2006).

10. Psoriasis

[00177] Arginase I is highly overexpressed in the hyperproliferative psoriatic epidermis in human skin, and therefore arginase inhibitors may be useful in the treatment of psoriasis. See, e.g., Bruch-Gerharz et al., Am. J. Pathology 162, 203-11 (2003).

11. Rheumatoid Arthritis

[00178] Arginase II is upregulated in synovial fluid from human patients, and therefore arginase inhibitors may be useful in the treatment of arthritis. See, e.g., Huang et al., Kaohsiung J. Med. Sci. 17, 358-63 (2001); Corraliza and Moncada, J. Rheumatol. 29, 2261-65 (2002).

12. Peyronie's Disease

[00179] The compounds of the invention may be useful in the treatment or prevention of Peyronie's disease. Arginase II is upregulated in the rat penis in an animal model for this disease. See, e.g., Bivalacqua et al., J. Andrology 22, 497-506 (2001). While this disorder can contribute to erectile dysfunction, it is principally an inflammatory condition in which fibrotic tissue builds up in the penis.

13. General

[00180] The composition of the invention can be used to treat a disorder in a mammal, wherein the disorder is associated with expression of an abnormally high level of arginase activity in a tissue of the mammal. Because NO synthase activity is regulated in a reciprocal fashion with respect to arginase activity in mammals, more particularly humans, the compounds and compositions of the invention can be used to treat a disorder in a mammal, wherein the disorder is associated with expression of an abnormally low level of NO synthase activity in a tissue of the mammal. Since the reciprocal interaction of arginase and NO synthase has implications for the function of smooth muscle, the use of the compounds described herein for the regulation of smooth muscle activity in an animal is also contemplated in the invention. Of course, a compound of the invention or a composition comprising the compound of the invention which comprises an arginase inhibitor described herein can also be used to inhibit arginase in a mammal having normal levels of arginase and NO synthase activity, particularly where the physiology which is desired to be effected is one which is affected by arginase or NO synthase activity, or where a disorder which is not caused by aberrant arginase or NO synthase activity levels can nonetheless be alleviated or inhibited by inhibiting arginase activity (e.g., certain forms of erectile dysfunction).

[00181] The invention also includes a method of enhancing smooth muscle relaxation comprising contacting the smooth muscle with an arginase inhibitor. The smooth muscle is preferably within the body of an animal. The type of smooth muscle to be relaxed includes, but is not limited to, gastrointestinal smooth muscle, anal sphincter smooth muscle, esophageal sphincter muscle, sphincter of Oddi, arterial smooth muscle, heart smooth muscle, pulmonary smooth muscle, kidney smooth muscle, uterine smooth muscle, vaginal smooth muscle, cervical smooth muscle, placental smooth muscle, and ocular smooth muscle. When the smooth muscle is gastrointestinal smooth muscle, the type of gastrointestinal smooth muscle includes, but is not limited to, the internal anal sphincter muscle.

[00182] When the smooth muscle is within the body of the animal, the invention includes a method of alleviating (e.g., reducing the incidence or severity) or inhibiting (e.g., reducing the likelihood of developing, or preventing) an arginase-related disorder in an animal. In a preferred embodiment, the animal is a human.

[00183] To alleviate an arginase-related disorder in a mammal, an arginine inhibitor described herein is administered to a mammal afflicted with the disorder. The inhibitor is preferably administered in combination with one or more pharmaceutically acceptable carriers, as described in further detail herein. The inhibitor (preferably in combination with a carrier) can also be administered to a mammal afflicted with a disorder characterized by aberrant NO synthase activity, or to one which exhibits normal (i.e. non-diseased) levels of arginase and NO synthase activities, but in which inhibition of arginase activity is desired. The invention also contemplates use of an arginase inhibitor in an *in vitro* arginase inhibition/smooth muscle relaxation functional assay, for the purpose of identifying compounds which affect smooth muscle function. Compounds so identified are considered to be candidate arginase inhibitor antagonists, in that these compounds are identified by their ability to counteract the inhibition of arginase activity. For example, these compounds may be identified by using an assay for smooth muscle activity using the internal anal sphincter muscle and one of the arginase inhibitors of the invention. In this assay, strips of the internal anal sphincter muscle obtained from a mammal (e.g., an adult opossum) are induced to relax by NANC nerve-mediated relaxation using electrical field stimulation (EFS); relaxation is reversed by contacting the muscle strips with arginase; and reversal of relaxation is accomplished by contacting the muscle with an arginase

inhibitor. To identify an arginase inhibitor antagonist, the muscle strips are then subsequently contacted with a test compound. The effect of the test compound on subsequent reversal of muscle relaxation is assessed. Any significant reversal of the relaxation state of the muscle in the presence of the test compound, compared with the relaxation state of the muscle in the absence of the test compound, is an indication that the test compound is an arginase inhibitor antagonist.

[00184] Accordingly, in certain embodiments, the invention is directed to methods of inhibiting arginase in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of formula Ia or formula Ib or a pharmaceutically acceptable salt thereof.

[00185] Accordingly, in certain embodiments, the invention is directed to methods of treating an arginase-related disorder in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of formula Ia or formula Ib or a pharmaceutically acceptable salt thereof. In certain preferred embodiments, the arginase-related disorder is a disorder associated with an abnormally low level of nitric oxide synthase activity in a tissue of the human, a disorder associated with an abnormally high level of arginase activity in a tissue of the human, or combinations thereof, including heart disease, systemic hypertension, pulmonary hypertension, erectile dysfunction, autoimmune encephalomyelitis, chronic renal failure, gastrointestinal motility disorders, gastric cancers, reduced hepatic blood flow, insufficient hepatic blood flow, cerebral vasospasm, or a combination thereof.

[00186] In still other certain embodiments, the invention is directed to methods of relaxing smooth muscle in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of formula Ia or formula Ib or a pharmaceutically acceptable salt thereof. In certain preferred embodiments, the smooth muscle which is relaxed according to this method is at least one selected from the group consisting of a gastrointestinal smooth muscle, anal sphincter smooth muscle, esophageal sphincter muscle, corpus cavernosum, sphincter of Oddi, arterial smooth muscle, heart smooth muscle, pulmonary smooth muscle, kidney smooth muscle, uterine smooth muscle, vaginal smooth muscle, cervical smooth muscle, placental smooth muscle, and ocular smooth muscle.

[00187] In certain embodiments, the invention is directed to methods of treating a disease or condition associated with upregulation of arginase in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of formula Ia or formula Ib or a pharmaceutically acceptable salt thereof;

wherein said disease or condition is a gastrointestinal disease, a pulmonary inflammatory disease, a sexual arousal disorder, a cardiovascular disorder, a hemolytic disorder, an autoimmune disease, wound healing, a disease caused by parasitic protozoa, a disease caused by bacteria, a cancer, pre-term labor, psoriasis, or a combination thereof.

[00188] Inhibiting arginase impacts cancer in two ways. The first way is relief from immune-suppression that leads to tolerance of the tumor and the second way is by restricting the production of ornithine and subsequent polyamines, which have a role in proliferation.

[00189] In certain preferred embodiments, the gastrointestinal disease is a gastrointestinal motility disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, adenotonsillar disease or a combination thereof.

[00190] In certain preferred embodiments, the pulmonary inflammatory disease is asthma, chemically-induced lung fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD) or a combination thereof.

[00191] In certain preferred embodiments, the sexual arousal disorder is male erectile dysfunction, Peyronie's Disease, or a female sexual arousal disorder.

[00192] In certain preferred embodiments, the cardiovascular disorder is endothelial vascular dysfunction in atherosclerosis, hypertension, ischemia reperfusion injury, peripheral vascular disease, peripheral arterial disease, subarachnoid hemorrhage, hypercholesterolemia, diabetes, or a combination thereof, diabetic cardiovascular disease, pulmonary arterial hypertension, Reynaud's disease, or a combination thereof.

[00193] In certain preferred embodiments, the hemolytic disorder is paroxysmal nocturnal hemoglobinuria (PNH), sickle-cell disease, thalassemias, hereditary spherocytosis and stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, ABO mismatch transfusion reaction, paroxysmal cold hemoglobinuria, severe idiopathic autoimmune

hemolytic anemia, infection-induced anemia, malaria, cardiopulmonary bypass, mechanical heart valve-induced anemia, chemical induced anemia, or a combination thereof.

[00194] In certain preferred embodiments, the autoimmune disease is encephalomyelitis, multiple sclerosis, anti-phospholipid syndrome 1, autoimmune hemolytic anaemia, chronic inflammatory demyelinating polyradiculoneuropathy, dermatitis herpetiformis (“Celiac Disease”), dermatomyositis, myasthenia gravis, pemphigus, rheumatoid arthritis, stiff-person syndrome, type 1 diabetes, ankylosing spondylitis, or a combination thereof.

[00195] In certain preferred embodiments, the condition is wound healing.

[00196] In certain preferred embodiments, the disease caused by parasitic protozoa is African sleeping sickness, Chagas’ disease, leishmaniasis, malaria, or a combination thereof.

[00197] In certain preferred embodiments, the cancer is renal cell carcinoma, prostate cancer, colorectal cancer, breast cancer, skin cancer, lung cancer, ovarian cancer, gastric cancer, or a combination thereof. In certain embodiments, the skin cancer is a squamous cell cancer, basal cell cancer, or a combination thereof.

[00198] In certain preferred embodiments, the condition is pre-term labor.

[00199] In certain preferred embodiments, the condition is Reynaud’s disease.

[00200] In certain embodiments, the invention is directed to methods of providing relief from immune suppression in a mammal, comprising the step of:

administering to said mammal an effective amount of a compound of formula Ia or formula Ib or a pharmaceutically acceptable salt thereof;

wherein said mammal is suffering from a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.

[00201] In certain embodiments, the invention is directed to methods of inhibiting the production of ornithine in a mammal suffering from at least one tumor, comprising the step of:


administering to said mammal an effective amount of a compound of formula Ia or formula Ib or a pharmaceutically acceptable salt thereof.

[00202] In addition, the compounds and compositions of the invention are useful as anti-fungicides in agriculturally or otherwise economically important plant life. The compounds and compositions of the invention can be therapeutically administered to a plant by spraying or other means well known in the art of plant biology.

Synthesis of Arginase Inhibitors

[00203] The compounds of the present invention may be prepared in a number of ways well known to those skilled in the art. The compounds can be synthesized, for example, by the methods described below, or variations thereon as appreciated by the skilled artisan. Variables used are as defined for formula Ia or formula Ib, unless otherwise noted. The reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.


[00204] In accordance with this invention, the boronic acid derivatives (where Z is



in the compounds of formula Ia or formula Ib) may be prepared as generally described in Schemes 3-17 (which schematically illustrate the synthesis of several exemplary compounds of the invention), discussed below.

[00205] The compounds of formula IA or formula IB containing a double bond between X^3 and X^4 may be prepared in accordance with the synthetic scheme set forth in Collet, et al. (2000) *J. Chem. Soc., Perkin Trans. 1*, 177-182 with the appropriately substituted R^1 group.


[00206] In accordance with this invention, the N-hydroxy guanidine derivatives (where Z is



and X^3 is $-(NR^2)-$ in the compounds of formula IA or formula IB and where the $C\alpha$ is substituted by R^1) may be prepared as generally described herein.

[00207] Scheme 3 schematically illustrates the solid-phase synthesis of compounds **1** of the present invention, where R^1 is generated from reagents that are “activated” alkyl halides, such as benzyl bromide.

Scheme 3




The Fmoc group of Fmoc-Gly-Wang resin is removed by methods well known in the art. Atherton and Sheppard, “The Fluorenylmethoxycarbonyl Amino Protecting Group,” in The

Peptides, Udenfriend and Meienhofer, Eds., Academic Press, New York (1987), vol. 9, p. 1). The amine is protected as the *N*-diphenylmethylene amine by treating the resin-bound free amine with excess benzophenone imine and glacial acetic acid in NMP. See, O'Donnell et al., Tetrahedron Lett., 38, 7163 (1997) resulting in compound **3**. This protected glycine is reacted with excess 2-(4-bromobutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**4a**) in the presence of an organic non-nucleophilic base such as BEMP or BTPP in NMP resulting in compound **5**. The reaction can be accelerated by the addition of tetrabutylammonium iodide or even more preferred the alkylating reagent can be the iodo derivative instead of the bromo compound. The second side chain can be introduced by treating **5** with a strong base such as *n*-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions and then adding another alkyl halide, such as benzyl bromide resulting in compound **6**. See, Griffith et al., Tetrahedron Lett. 38, 8821 (1997). The desired amino acid (**1**, wherein R¹ may be of a number of sidechains as described herein) can be released from the resin by treating with strong aqueous acid at high temperature (not shown) or, alternatively, the controlled deprotection and release of compound **1** can be completed in a stepwise manner as illustrated in Scheme 3.

[00208] Scheme 4 outlines an exemplary solid-phase synthesis of compound **1d** of the present invention, where R¹ is generated from reagents that are “unactivated” alkyl halides such as bromoethane.


Scheme 4



Compound **3** is reacted with excess alkyl halide in the presence of an organic non-nucleophilic base such as BEMP or BTTP in NMP resulting in compound **7**. The reaction can be accelerated by the addition of tetrabutylammonium iodide or even more preferred the alkylating reagent can be the iodo-derivative instead of the bromo-compound. The second side chain can be introduced after the amine protecting group is switched from the ketimine to an aldimine as shown in Scheme 4 by first treating compound **7** under mild aqueous acid, neutralizing the hydrochloride salt, and then reacting compound **8** with a benzaldehyde under dehydrating conditions to give compound **9**. This intermediate was reacted with 2-(4-iodobutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**4b**) and BTTP in NMP to give compound **10**. See, Scott, Tetrahedron Lett. 38, 3695 (1997). Amino acid **1d** can be released from the resin by treating with strong aqueous acid at high temperature (not shown) or, alternatively, by controlled deprotection and release of compound **1d** by the stepwise process illustrated in Scheme 4.

[00209] Scheme 5 outlines the solid-phase synthesis of some compounds of the present invention where R¹ is generated from reagents such as bromomethylpyridine that may be unstable to KHMDS or other very strong bases.


Scheme 5



According to this method, compound **5** is treated with mild aqueous acid followed by neutralization of the hydrochloride salt to produce **11**. This intermediate is protected as the aldimine **12**, which is then treated with excess alkylating agent and BTPP in NMP to give intermediate **13** (Scott, W. L., Tetrahedron Lett. 1997, 38:3695). The desired amino acid (**1e**) is released from the resin by treating with strong aqueous acid at high temperature (not shown) or, alternatively, the controlled deprotection and release of **1e** can be done stepwise as shown in Scheme 5.

[00210] Scheme 6 schematically illustrates the solution-phase syntheses of useful starting materials **16a** (wherein R = methyl), **16b** (wherein R = ethyl), and **16c** (wherein R = tert-butyl) and alkylating reagents **4a** and **4b**.


Scheme 6



In the first reaction at the top of Scheme 6, the hydrochloride salt of a glycine alkyl ester **14a-c** is reacted with benzophenone imine, O'Donnell, et al., J. Org. Chem. 47, 2663 (1982), at room temperature to give the corresponding ketimine protected glycine ester **16a-c**. This transimination is particularly useful for *tert*-butyl ester **16c**. Alternatively, alkyl esters of α -bromoacetic acid **15a-c** can be reacted with benzophenone in refluxing acetonitrile as shown in the second reaction resulting in **16a-c**. O'Donnell, Acc. Chem. Res. 37, 506 (2004).

[00211] Scheme 7 illustrates a solution-phase synthesis of compound **1** of the present invention where R^1 is generated from reagents that are “activated” alkyl halides, such as benzyl bromide.


Scheme 7



Compound **16** is reacted with LiHMDS at low temperature as described in Reddy et al., Org. Biomol. Chem. 5, 889 (2007), and then 1 equivalent of reagent **4b** is added and allowed to react at room temperature for several hours to give intermediate compound **18**. The second side chain is introduced by treating compound **18** with a strong base such as *n*-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding another alkyl halide, such as benzyl bromide, resulting in compound **19**. Compound **19** is globally deprotected by treating with strong aqueous acid to give compound **1** (wherein R^1 may be of a number of sidechains as described herein).

[00212] Scheme 8 outlines an exemplary solution-phase synthesis of compound **1** of the present invention, where R^1 is generated from a variety of alkyl halides including poorly reactive reagents.


Scheme 8



Compound **16** is reacted with LiHMDS at low temperature as described in Reddy et al., Org. Biomol. Chem. 5, 889 (2007), and then 1 equivalent of R¹-X (wherein R¹ may be of a number of sidechains as described herein) is added and allowed to react at room temperature for several hours to give compound **20**. The second side chain (R¹) can be introduced by treating intermediate compound **20** with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of crotyl bromide to give compound **21**. Hydroboration of the crotyl side chain to give the boronate ester side chain is accomplished by treatment with pinacol borane in the presence of iridium catalyst similar to that reported by Yamamoto et al., Tetrahedron 60, 10695 (2004), to give compound **19**, which is globally deprotected by treating with strong aqueous acid to give compound **1**.

[00213] Scheme 9 illustrates an exemplary solution-phase synthesis of compound **1** of the present invention, where R^1 is generated from a set of alkyl halides such as α -haloacetate esters.

Scheme 9




Functionalities of this type provide intermediates with multiple sites of alkylation for the next reaction. Therefore, introduction of the crotyl side chain first is preferred for this compound class. Compound **16** is treated with 1.5 eq of BTTP (or BEMP) and crotyl bromide at room temperature for several hours, O'Donnell, J. Acc. Chem. Res. 37, 506 (2004) to give compound **22**. The R^1 side chain can be introduced by treating compound **22** with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of R^1 -X to give compound **21**. Hydroboration of the crotyl side chain to give the boronate ester side chain is accomplished by treatment with pinacol borane in the presence of iridium catalyst similar to that reported by Yamamoto et al., Tetrahedron 60, 10695

(2004), to give compound **19**, which is globally deprotected by treating with strong aqueous acid to give compound **1** (wherein R^1 may be of a number of sidechains as described herein).

[00214] Scheme 10 outlines an exemplary solution-phase synthesis of compound **1** of the present invention where R^1 is generated from commercially available amino acids or esters such as L-leucine-*tert*-butyl ester HCl.

Scheme 10




Compound **20** is prepared from these commercially available amino esters as described in Scheme 6. The second side chain (R^1) can be introduced by treating compound **20** with a strong base such as *n*-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of crotyl bromide to give intermediate compound **21**. Hydroboration of the crotyl side chain to give the boronate ester side chain is accomplished by treatment with pinacol borane in the presence of iridium catalyst similar to that reported by Yamamoto et al., *Tetrahedron* 60, 10695 (2004), to give compound **19**, which is globally deprotected by treating with strong aqueous acid to give compound **1** (wherein R^1 may be of a number of sidechains as described herein).

[00215] It should be noted that many R^1 -X reagents used in the synthetic chemistry of Schemes 3-10 are not commercially available. In such cases, they were made, for example, by

the exemplary reactions outlined in Scheme 11, among other methods. For example, although Scheme 11 illustrates the use of a phenol starting material, the synthesis could be readily adapted to other similar starting materials, such as piperidine, piperazine, and morpholine compounds. Likewise, compound **27** could also be any of a variety of homologous compounds.

Scheme 11




[00216] Referring to the top of Scheme 11, compound **25** is prepared by reacting substituted or unsubstituted phenols with 3-bromo-1-propanol in the presence of a base, such as potassium carbonate, at elevated temperature for several hours. Upon isolation of product **25**, it is converted to the alkyl iodide by reaction with iodine in the presence of imidazole and

triphenylphosphine. Alternatively, resin-bound triphenylphosphine can also be used to give compound **25** that can be used in various alkylation steps as R^1 -X in accordance with the methods hereof.

[00217] As illustrated at the bottom of Scheme 11, amine-containing R^1 side chains can be introduced into compound **1** by preparing R^1 -X alkylating reagents such as compound **31** by first reacting starting material **26** with di-*tert*-butyl dicarbonate to give compound **27**, which is subsequently *O*-protected by treating it with TBS-Cl and imidazole to give di-protected intermediate **28**. The base labile carbamate is further protected by another treatment with di-*tert*-butyl dicarbonate in the presence of dimethylaminopyridine to give tri-protected intermediate **29**. The TBS ether is removed by treating with fluoride ion in organic solvent to give alcohol **30**. Finally, alkyl iodide **31** is prepared in analogous manner as described above for the synthesis of compound **25**.

[00218] Scheme 12 outlines the synthesis of exemplary compounds **38**, **39**, and **40** of the present invention where the R^1 sidechain is made by selective chemistry performed upon a primary amine and subsequent manipulation of this amine in R^1 .

Scheme 12




Referring to the top of Scheme 12, compound **33** is generated by the methods outlined in Schemes 8 and 11. Anhydrous cleavage of the Boc protecting groups results in the primary amine **33**. This primary amine can be capped with acyl groups by reacting with acid chlorides to give compound **34**. Alternatively, compound **33** can be reacted with isocyanates in the presence of a tertiary amine to give urea **35**. Additionally, compound **33** can be reacted with sulfonyl

chlorides in the presence of a tertiary amine to give sulfonamide **36**. Each of intermediates **33-36** can be further deprotected by a two-step process involving hydrolysis of the ketimine and then transesterification of the pinacol boronic ester by treating with an excess of phenyl boronic acid in a biphasic mixture to give final products **37-41**.

[00219] Scheme 13 outlines the synthesis of *N*-alkylated compounds **63** and **64** in the present invention where R¹ includes a primary amine being converted to a secondary or tertiary amine. This methodology can also be used to prepare compounds with side chains containing a cyclic amine such as a piperidine or piperazine and the terminal amine is alkylated similarly.

Scheme 13




Compound **33** from Scheme 12 can be treated with either one equivalent of an alkyl halide such as benzyl bromide to give compound **61** or alternatively it can be treated with two equivalents of an alkyl halide to give compound **62**. Both of these compounds can be deprotected by any of the globally deprotecting procedures to give compounds **63** and **64**, respectively, which are

derivatives of compound **1**. This reaction scheme will also work for alkylating piperidine- and piperazine-containing compounds.

[00220] Scheme 14 outlines an exemplary asymmetric synthesis of ABH compound **1** in the present invention where R^1 is from a variety of alkyl halides.

Scheme 14




Compound **41** is asymmetrically alkylated in the presence of **45** under phase transfer conditions resulting in **42** with the desired *S* chirality in high %ee (enantiomeric excess) of >95%. See, Ooi et al., J. Am. Chem. Soc. 122, 5228 (2000); and Jiang et al., Org. Proc. Res. Dev. 12, 1164

(2008). Conversion of imine **42** to acetate **43** results in an intermediate that can be hydroborated under conditions illustrated in Scheme 8. Compound **1** with the desired *S* chirality is then produced by deprotection of all of the masking functionalities. Alternatively, chiral compound **1** can be prepared by separating any disubstituted intermediate by chiral chromatography.

[00221] Scheme 15 illustrates an exemplary asymmetric synthesis of compound **1ar** where R^1 side chain is specifically a CH_2OH group.


Scheme 15



Oxazoline **46** is prepared by acylating a serine derivative with an aryl acid chloride such as 2-naphthoic acid chloride, and then dehydrating the intermediate with DAST ((diethylamino)sulfur trifluoride). Compound **46** is alkylated by treating with crotyl bromide in the presence of a base, such as CsOH, to give chiral intermediate **47**. This intermediate can be analyzed by chiral chromatography to ascertain the amount of enantiomeric enrichment. Boronic ester **48** is introduced by the hydroboration process described above and the final product is isolated by strong acid cleavage of the protecting groups. Alternatively, the racemic analog of compound **47** can be obtained by reaction of a strong base such as BTPP in the absence of chiral catalyst **45**. The desired enantiomer thereafter is be obtained by chiral chromatography.

[00222] Scheme 16 outlines the synthesis of norNOHA compounds **47** in the present invention where R¹ is from a variety of alkyl halides.

Scheme 16




Starting material **16c** is preferred to avoid lactam formation during the synthesis of these compounds. Compound **16c** is treated with a base, e.g., LiHMDS, at low temperature under an argon atmosphere and the 1 equivalent of R^1-X is added to give compound **20**. This is subsequently treated with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of α -

bromoacetonitrile to give **49**. The amine is deprotected and reprotected with a Boc group to give intermediate **50**. The nitrile is reduced by catalytic hydrogenation using PtO_2 , Xue et al., J. Org. Chem. 60, 946 (1995), to give the primary amine **51**. This primary amine is transformed into the *N*-hydroxy guanidine group by the series of synthetic steps of cyanamide formation and reaction with hydroxylamine as reported by Custot et. al., J. Am. Chem. Soc. 119, 4086 (1997). Deprotection to final product **54** proceeds by treatment with $\text{HCl}/\text{H}_2\text{O}$.

[00223] Scheme 17 outlines the asymmetric synthesis of nor-NOHA compound **54** in the present invention where R^1 is from a variety of alkyl halides.


Scheme 17



Compound **41** is asymmetrically alkylated in the presence of catalyst **45** under phase transfer conditions resulting in compound **55** with the desired *S* chirality in high %ee (>95%). See, Ooi et al., J. Am. Chem. Soc. 122, 5228 (2000); and Jiang et al., Org. Proc. Res. Dev. 12, 1164 (2008). Amine **55** is deprotected and reprotected with a Boc group to give compound **56**. Nitrile **56** is reduced by catalytic hydrogenation using PtO₂, (Xue et al., J. Org. Chem. 60, 946 (1995) to give primary amine **57**. The primary amine is transformed into the *N*-hydroxy guanidine group by the series of synthetic steps of cyanamide formation and reaction with hydroxylamine as reported by Custot et. al., J. Am. Chem. Soc. 119, 4086 (1997). Deprotection to the final product **54** with the desired *S* chirality proceeds by treatment with strong acid to cleave the Boc group.


[00224] Scheme 18 illustrates some known arginase inhibitors and several improved analogs thereof in accordance with certain embodiments of the invention.

Scheme 18




[00225] Some examples of suitable R^1 groups are presented in Schemes 19-24, below (which illustrate some exemplary R^1 sidechains according to certain embodiments of the present invention). Using the synthetic chemistry methodology discussed herein above, the arginase inhibitors of the present invention having these and other R^1 sidechains made be readily prepared in accordance with these principles.


Scheme 19




Scheme 20



Scheme 21




Scheme 22




for example,
R* = halo,
alkyl, aryl,
alkoxy

Scheme 23



alkyl chain can be varied
The rings could also be piperidones and pyrrolidinones

Scheme 24



[00226] As will be readily understood, functional groups present may contain protecting groups during the course of synthesis. Protecting groups are known *per se* as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. Protecting groups that may be employed in accordance with the present invention may be described in Greene, T.W. and Wuts, P.G.M., *Protective Groups in Organic Synthesis* 2d. Ed., Wiley & Sons, 1991.

[00227] The compounds of this invention contain chiral centers, providing for various stereoisomeric forms such as diastereomeric mixtures, enantiomeric mixtures as well as optical isomers. The individual optical isomers can be prepared directly through asymmetric or stereospecific synthesis or by conventional chiral separation of optical isomers from the enantiomeric mixture.

[00228] Some of the compounds of the present invention may contain chiral centers (beyond the C α) and such compounds may exist in the form of stereoisomers (i.e. enantiomers). The present invention includes all such stereoisomers and any mixtures thereof including racemic mixtures. Racemic mixtures of the stereoisomers as well as the substantially pure stereoisomers are within the scope of the invention. The term “substantially pure,” as used herein, refers to at least about 90 mole %, more preferably at least about 95 mole %, and most preferably at least about 98 mole % of the desired stereoisomer is present relative to other possible stereoisomers. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by methods described herein. See, for example, Jacques, et al., *Enantiomers, Racemates and Resolutions* (Wiley Interscience, New York, 1981); Wilen, S.H., et al., *Tetrahedron*, 33:2725 (1977); Eliel, E.L. *Stereochemistry of Carbon Compounds*, (McGraw-Hill, NY, 1962); Wilen, S.H. *Tables of Resolving Agents and Optical Resolutions*, p. 268 (E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972).

[00229] The present invention includes prodrugs of the compounds of formula Ia or formula Ib. "Prodrug," as used herein, means a compound which is convertible *in vivo* by metabolic means (e.g., by hydrolysis) to a compound of formula Ia or formula Ib. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), *Design of Prodrugs*, Elsevier (1985); Widder, et al. (ed.), *Methods in Enzymology*, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs," *Textbook of Drug Design and Development*, Chapter 5, 113-191 (1991), Bundgaard, et al., *Journal of Drug Deliver Reviews*, **1992**, 8:1-38, Bundgaard, *J. of Pharmaceutical Sciences*, **1988**, 77:285 *et seq.*; and Higuchi and Stella (eds.) *Prodrugs as Novel Drug Delivery Systems*, American Chemical Society (1975).

[00230] Further, the compounds of formula IA or formula IB may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purpose of the present invention.

EXAMPLES

[00231] Compounds of the invention can be prepared by one or more of the following general methods. All parts and percentages are by weight, unless otherwise stated. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of such ranges therein are intended to be included as specific embodiments hereof. It should be understood that these examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. So that these synthetic methods may be more fully understood, some examples of solid-phase and solution-phase protocols for making specific compounds are also presented. All of the starting materials are commercially available or may prepared by procedures described in these schemes or by procedures that would be well known to one of ordinary skill in organic chemistry.

**General Procedure A. Preparation of Amino Ester Ketimine
from Amino Ester Hydrochloride**

[00232] Referring to Scheme 6, glycine ethyl ester hydrochloride **14b** (2.015 g, 14.4 mmol) was suspended in 25 mL dry DCM (dichloromethane) and benzophenone imine (2.42 mL, 14.4 mmol) was added and stirred at room temperature for 8-16 hr. The reaction mixture was filtered, washed with 5 mL DCM and the organic solution was washed 1x with H₂O and 1x with brine (a saturated aqueous solution of sodium chloride). The DCM was dried by filtering over a bed of HydromatrixTM brand diatomaceous earth and concentrating to dryness *in vacuo*. The product **16b**, an oil (2.83 g, 74%), was used without further purification. MS (LC/MS, ESI): 268 (M+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.5-8.0 (m, 10H), 4.5 (s, 2H), 4.0 (q, 2H), 1.2 (t, 3H). See, O'Donnell et al., J. Org. Chem. 47, 2663 (1982).

[00233] Although this synthesis is described with reference to the ethyl ester, the corresponding methyl and *tert*-butyl esters, as illustrated in Scheme 6, may also be made by adapting this procedure.

**General Procedure B. Alkylation of Glycine Ketimine
with Unactivated Alkyl Halides**

[00234] Referring to Scheme 7, compound **16** (1 mmol) was dissolved in 5 mL dry THF (tetrahydrofuran) under argon and cooled to -78°C. A 1 M solution of base, LiHMDS (lithium hexamethyldisilazane), in THF (1.05 mL) was added to the reaction mixture and stirred at -78°C for 45 minutes, and then an alkyl halide such as compound **4b** (1.05 mmol) in 3 mL dry THF was added. The reaction mixture was stirred at -78°C for 30 minutes and then allowed to warm to room temperature and stirred for 8-18 hr. The desired product (compound **18**) was isolated by diluting the reaction mixture with 20 mL EtOAc (ethyl acetate) and washing this organic solution with water and then brine. The organic solution was dried by filtering over a bed of HydromatrixTM brand diatomaceous earth and concentrating to dryness. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluting with mixtures of EtOAc/hexane (1-5%).

**General Procedure C. Alkylation of Amino Ester Ketimine
with Alkyl Halides**

[00235] Still referring to Scheme 7, compound **18** (1 mmol) was dissolved in 5 mL dry THF under argon and cooled to -78°C. A 0.5 M solution of KHMDS (potassium hexamethyl-disilazane) in toluene (1.05 mL) was added to the reaction mixture and stirred at -78°C for 45 minutes, and then the alkyl halide R¹-X (1.05 mmol), such as benzyl bromide, in 3 mL dry THF was added. The reaction mixture was stirred at -78°C for 30 minutes and then allowed to warm to room temperature and stirred for 8-18 hr. The desired product (compound **19**) was isolated by diluting the reaction mixture with 20 mL EtOAc and washing this organic solution with water and then brine. The organic solution was dried by filtering over a bed of HydromatrixTM brand diatomaceous earth and concentrating to dryness. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluting with mixtures of EtOAc/hexane (1-5%).

**General Procedure D. Alkylation of Glycine Ketimine
with Activated Alkyl Halides**

[00236] Referring to Scheme 9, compound **16** (1 mmol) was dissolved in 5 mL dry DCM under argon. Crotyl bromide (1.5 mmol) and BTPP (*tert*-butylimino-tri(pyrrolidino)-phosphorane, 1.5 mmol) were added to the reaction mixture and stirred at room temperature for 4-18 hr. The desired product (compound **22**) was purified by concentrating the reaction mixture to a puddle, redissolving in a small amount of DCM, applying it to a dry silica gel column, and eluting with mixtures of EtOAc/hexane (0.5-2%).

General Procedure E. Hydroboration of Crotyl Sidechain

[00237] Still referring to Scheme 9, under an argon atmosphere [Ir(cod)Cl]₂ (34 mg, 0.05 mmol, 5 mol%) and DPPM (bis(diphenylphosphino)methane, 38 mg, 0.10 mmol, 10 mol%) were dissolved in 5 mL dry DCM. Pinacol borane (175 µL, 1.20 mmol) and compound **21** (1 mmol) were dissolved in 5 mL dry DCM and added. The reaction mixture was stirred at room temp for 24 hr. The reaction was quenched by adding 1 mL of MeOH/H₂O (1:1), concentrating the reaction mixture *in vacuo*, diluting the reaction mixture with 20 mL EtOAc, and washing this

organic solution with water and then brine. The organic solution was dried by filtering over a bed of Hydromatrix™ brand diatomaceous earth and concentrating it to dryness. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluted with mixtures of EtOAc/hexane (5-10%) to give pure compound **19**.

**General Procedure F. Global Deprotection Procedure
for Removal of Nitrogen Protecting Groups**

[00238] Still referring to Scheme 9 (also illustrated in Scheme 7), compound **19** was dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70°C. This reaction mixture was cooled and extracted 3x with EtOAc. The aqueous layer was concentrated to a puddle and redissolved in 5 mL 1 N HCl and filtered over a plug of Dowex® 50WX8 ion exchange resin in the acidic form. This plug was washed with H₂O and then the desired product was eluted with 2 N NH₄OH. The basic solution was concentrated *in vacuo* to dryness, and the residue was dissolved in 10 mL 1 N HCl and lyophilized to produce purified compound **1**.

General Procedure G. Alternative Deprotection Procedure

[00239] An alternative method for removing the imine protecting group is exemplified in Scheme 12. According to this procedure, compound **33** was dissolved in 1 N HCl and stirred at room temperature for 2 hr. To this reaction mixture was added 10 equivalents of phenyl boronic acid and diethyl ether. The reaction mixture was rapidly stirred at room temperature for 12-18 hr. The layers were separated and the aqueous solution was washed 2x with diethyl ether. The aqueous solution was concentrated *in vacuo* to dryness and the residue dissolved in 1 N HCl and lyophilized to produce purified amine **37**.

General Procedure H. Synthesis of Aryl Ether Alkyl Iodides 25

[00240] Referring to Scheme 11, phenol **23** (3.0 mmol) and 3-bromo-1-propanol (3.75 mmol) were dissolved in 15 mL of 2-butanone. Solid K₂CO₃ (6.0 mmol) was added and the reaction stirred at reflux for 18-24 hr. The mixture was allowed to cool to room temperature and diluted with EtOAc, washed 3x with water and 1x with brine. The organic solution was dried

over magnesium sulfate and concentrated *in vacuo* to give oil **24**. Product compound **24** was assayed by LC/MS and ^1H NMR, and it used without further purification.

[00241] Still referring to Scheme 11, imidazole (6.0 mmol) and triphenylphosphine (3.3 mmol) were dissolved in 15 mL DCM and cooled to 0°C under argon. Iodine (3.3 mmol) was added to this mixture and stirred for 10-15 minutes. Alkyl alcohol **24** was added in 10 mL DCM and the reaction mixture was allowed to warm to room temperature and then stirred for 12-18 hr. A few mL of saturated sodium thiosulfate solution was added along with 10-15 mL water and the mixture was stirred for 10-15 minutes. The mixture was separated and the organic layer washed 3x with water and 1x with brine. The organic solution was dried over magnesium sulfate and concentrated *in vacuo* to give a solid residue. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluted with mixtures of EtOAc/hexane (5-10%) to give purified compound **25**. This compound is useful as an alkylating reagent in accordance with the synthesis methods described herein.

[00242] The foregoing reaction also was performed using resin-bound triphenylphosphine in slight molar excess in a similar procedure. In this case, these products **25** were normally used without purification over silica gel.

General Procedure I. Synthesis of Boc-Protected Amino Alkyl Iodides 31

[00243] Referring to Scheme 11, amino alcohol **26** was Boc-protected by treating it with 1.1 equivalents of di-*tert*-butyl dicarbonate in DCM at room temperature for 2-4 hr. The mixture was washed 2x with 1 N HCl and 1x with brine. The organic solution was dried over magnesium sulfate and concentrated *in vacuo* to give compound **27**, which was used without further purification.

[00244] Still referring to Scheme 11, compound **27** was treated with 2.5 equivalents imidazole and 1.1 equivalents of *tert*-butyl(chloro)dimethylsilane in DMF (*N,N*-dimethylformamide) at room temperature for 12-18 hr. The reaction mixture was diluted with EtOAc and this organic mixture was washed 3x with water and 1x with brine. The organic solution was

dried over magnesium sulfate and concentrated *in vacuo* to give di-protected compound **28**, which was used without further purification.

[00245] Next, compound **28** was treated with 2 equivalents of di-*tert*-butyl dicarbonate and 0.2 equivalents of dimethylaminopyridine in acetonitrile while stirring at room temperature for 36-48 hr. The reaction mixture was concentrated to dryness and the residue dissolved in EtOAc. This solution was washed 3x with 0.1 N HCl and 1x with brine, dried over magnesium sulfate, filtered, and concentrated *in vacuo* to give compound **29** which was used without further purification.

[00246] Subsequently, compound **29** was treated with 1.5 equivalents TBAF (tetrabutylammonium fluoride) in THF under argon at room temperature for 3-5 hr. This mixture was diluted with EtOAc and washed 3x with water and 1x with brine. The organic solution was dried over magnesium sulfate and concentrated *in vacuo* to give di-Boc compound **30**, which was used without further purification.

[00247] Finally, imidazole (6.0 mmol) and triphenylphosphine (3.3 mmol) were dissolved in 15 mL DCM and cooled to 0°C under argon. Iodine (3.3 mmol) was added to this mixture and stirred for 10-15 minutes. Alkyl alcohol **30** was added in 10 mL DCM and the reaction mixture was allowed to warm to room temperature and then stirred for 12-18 hr. A few mL of saturated sodium thiosulfate solution was added along with 10-15 mL water and the mixture was stirred for 10-15 minutes. The mixture was separated and the organic layer washed 3x with water and 1x with brine. The organic solution was dried over magnesium sulfate and concentrated *in vacuo* to give compound **31**. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluted with mixtures of EtOAc/hexane (5-10%) to give purified compound **31**. This compound is useful as an alkylating reagent in accordance with the synthesis methods described herein.

***General Procedure J. Selective Boc Removal
and Acylation of Resulting Primary Amine***

[00248] Referring to Scheme 12, compound **32** is converted to compound **33** by treatment with 25-50% TFA (trifluoroacetic acid)/DCM under argon for 12-16 hr. The reaction mixture is

concentrated to dryness *in vacuo*, a few mL of DCM added and this solution is reconcentrated to dryness and then the residue dried *in vacuo* for several hr and then placed under an argon atmosphere.

[00249] Still referring to Scheme 12, this residue was added to 2-3 equivalents of a resin-bound amine base such as PS-DIEA (diisopropylethylamine) in DCM. To this was added 1 eq. of an acylating agent, such as acetic anhydride or benzoyl chloride, and the reaction mixture stirred or shaken for 12-16 hr. The reaction mixture was filtered and the resin washed with a few mL of DCM then a few mL of 1 N HCl/THF (1:2). The filtrates were combined and additional 1 N HCl added. This mixture was stirred vigorously at room temperature for 12-16 hr and the organic layer separated from the aqueous layer. The aqueous solution was washed 2x with ethyl acetate. The pinacol ester was removed by General Procedure G as described above and the resulting crude products (compounds **38**, **39**, and **40**) were purified by elution over a C₁₈ column with acetonitrile/water gradients with 0.075% TFA.

**General Procedure K. Preparation of Amino Ester Ketimine
from α -Bromo Acetate**

[00250] Referring to Scheme 6, benzophenone imine (6.68 mL, 40.0 mmol) and *tert*-butyl bromoacetate **15c** (5.9 mL, 40.0 mmol) were dissolved in 40 mL acetonitrile. DIEA (6.95 mL, 40.0 mmol) was added and the reaction mixture heated to reflux for 14 hr. The reaction mixture was cooled to room temperature, neutralized by the addition of 50% aqueous acetic acid, and cooled to 0°C. The resulting solids were collected by filtration and then washed with cold ethanol. Product **16c** was dried *in vacuo* to give 9.05 g (77%) which was used without further purification. MS (LC/MS, ESI): 296 (M+H), 240 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.5-8.0 (m, 10H), 4.5 (s, 2H), 1.4 (s, 9H). See, O'Donnell, Acc. Chem. Res. 37, 506 (2004).

General Procedure L. Preparation of Compound 4a


[00251] Referring to Scheme 6, 2-(4-bromobutyl)benzo[*d*][1,3,2]dioxaborole **17** (5.09 g, 20.0 mmol) was dissolved in 20 mL dry THF, pinacol (2.39 g, 20.1 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hr under argon. The reaction mixture was

concentrated *in vacuo*, 50 mL of hexane was added to the residue, and it was cooled at 0°C for 2 hr. The solids were filtered and the washed with 25 mL hexane, the filtrate further diluted with 300 mL hexane, and cooled at 0°C overnight. Again, the solids were filtered and washed with 25 mL hexane, another 300 mL hexane added to the filtrate and cooled at 0°C for 2 hr. No further solids were formed and this solution was concentrated *in vacuo*, dried *in vacuo*, and the resulting clear oil **4a** (5.24g, 99%) was stored under argon at 0°C. ¹H NMR (300 MHz, CDCl₃, δ): 3.5 (t, 2H), 1.8 (m, 2H), 1.4 (m, 2H), 1.2 (s, 12H), 0.7 (t, 2H).

General Procedure M. Preparation of Compound 4b

[00252] Still referring to Scheme 6, compound **4a** (5.0 g, 19.0 mmol) was dissolved in 40 mL dry acetone, sodium iodide (4.65 g, 31.0 mmol) was added and the reaction mixture was stirred overnight at room temperature under argon. The resulting solids were filtered and washed with diethyl ether. The filtrate was concentrated to a viscous oil which was diluted with 150 mL diethyl ether, washed 2 x with H₂O and 1x with brine, dried over sodium sulfate and concentrated *in vacuo* to a clear colorless oil **4b** (5.86g, 99%). ¹H NMR (300 MHz, CDCl₃, δ): 3.1 (t, 2H), 1.8 (m, 2H), 1.4 (m, 2H), 1.2 (s, 12H), 0.7 (t, 2H).

Example 1. 2-Amino-2-benzyl-6-boronoheptanoic acid hydrochloride (1a)



[00253] Compound **1a**, illustrated above, was synthesized via the reaction scheme illustrated in Scheme 3 (wherein R¹ is benzyl). Residual free hydroxyl groups on Fmoc-Gly-Wang resin **2** were acetylated by treating 5.0 g (0.85 mmol/g, 4.25 mmol) of resin **2** with acetic anhydride (1.0 mL, 10.6 mmol) and DMAP (4-dimethylaminopyridine, 100 mg, 0.82 mmol) in


50 mL of NMP (*N*-methyl-2-pyrrolidone) for 1 hr. The resin was filtered, washed 3x with DCM, 3x with alternating MeOH (methanol) and DCM, 3x with MeOH, then 4x with DCM. This resin was then treated with 75 mL 20% piperidine/DMF for 30 minutes followed by filtration and washing the resin as described above. The resin-bound amine was converted to the ketimine **3** by treating with benzophenone imine (8.6 mL, 51.2 mmol) and glacial acetic acid (2.2 mL, 38.4 mmol) in 60 mL NMP overnight followed by filtration and washing the resin as described above.

[00254] Still referring to Scheme 3, resin **3** was treated with a mixture of compound **4a** (11.2 g, 42.6 mmol, 10 eq), TBAI (tetrabutylammonium iodide, 15.7 g, 42.5 mmol, 10 eq) and BTTP (13.0 mL, 42.5 mmol, 10 eq) in 45 mL of NMP overnight followed by filtration and washing the resin as described above to give resin **5**, which was dried *in vacuo* to give 5.39 g. Subsequently, 305 mg of resin **5** (0.60 mmol/g, 0.18 mmol) was washed with 4 x 5 mL of dry THF under an argon atmosphere. 3.5 mL of dry THF was added to this resin followed by KHMDS in toluene (0.5 M, 1.8 mL, 0.90 mmol) and gently mixed at room temperature for 45 min. The reaction mixture was quickly filtered under an argon atmosphere and benzyl bromide (214 μ L, 1.8 mmol) in 5 mL dry THF was added and gently mixed for 24 hr. This reaction mixture was filtered, washed 3x THF/H₂O 2:1, 3x THF, 3x DCM, 3x alternating MeOH and DCM, and 4x DCM to give compound **6**, wherein R¹ is benzyl.

[00255] Still referring to Scheme 3, resin **6** was washed 3x THF/H₂O 2:1, and then it was treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3x THF/H₂O 2:1, 3x THF, and 4x DCM. This resin was immediately treated with 95% TFA/H₂O for 2 hr and the filtrate was collected, and the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated *in vacuo*. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70°C. This reaction mixture was cooled and extracted 3x with EtOAc. The aqueous layer was concentrated to a puddle and redissolved in 5 mL 1 N HCl and filtered over a plug of Dowex® 50WX8 ion exchange resin in the acidic form. This plug was washed with H₂O and then the desired product was eluted with 2 N NH₄OH. The basic solution was concentrated *in vacuo* to dryness and the residue was dissolved in 10 mL 1 N HCl and lyophilized to give 44 mg of compound **1a**, the chemical structure of which is illustrated

above. MS (LC/MS, ESI): 248 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 7.25-7.5 (m, 5H), 2.9-3.1 (m, 2H), 1.9 (t, 2H), 1.4-1.6 (m, 4H), 0.7 (t, 2H).

Example 2. 2-Allyl-2-amino-6-boronohexanoic acid hydrochloride (1b)




[00256] Referring again to Scheme 3 (wherein R¹ is allyl), 300 mg of resin **5** (0.60 mmol/g, 0.18 mmol) was washed with 4 x 5 mL of dry THF under an argon atmosphere. 3.5 mL of dry THF was added to this resin followed by KHMDS in toluene (0.5 M, 1.8 mL, 0.90 mmol) and gently mixed at room temperature for 45 min. The reaction mixture was quickly filtered under an argon atmosphere and the alkylating agent, allyl bromide (155 μ L, 1.8 mmol) in 5 mL dry THF, was added and gently mixed for 24 hr. This reaction mixture was filtered, washed 3x THF/H₂O 2:1, 3x THF, 3x DCM, 3x alternating MeOH and DCM, and 4x DCM to give resin **6**, wherein R¹ is allyl.

[00257] Still referring to Scheme 3, resin **6** was washed 3x THF/H₂O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3x THF/H₂O 2:1, 3x THF, and 4x DCM. This resin was immediately treated with 95% TFA/H₂O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated *in vacuo*. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70°C. This reaction mixture was cooled and extracted 3x with EtOAc. The aqueous layer was concentrated to a puddle and redissolved in 5 mL 1 N HCl and filtered over a plug of Dowex® 50WX8 ion exchange resin in the acidic form. This plug was washed with H₂O and then the desired product was eluted with 2 N NH₄OH. The basic solution was concentrated *in vacuo* to dryness and the residue was dissolved in 10 mL 1 N HCl and lyophilized to give 11 mg of compound **1b**, the chemical structure of which is illustrated

above. MS (LC/MS, ESI): 198 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 5.7-5.8 (m, 1H), 5.0-5.1 (m, 2H), 2.3-2.5 (m, 2H), 1.9 (t, 2H), 1.4-1.6 (m, 4H), 0.7 (t, 2H).

Example 3. 2-Amino-2-(4-boronobutyl)succinic acid hydrochloride (**1c**)




[00258] Referring again to Scheme 3 (wherein R¹ = carboxymethyl), 300 mg of resin **5** (0.60 mmol/g, 0.18 mmol) was washed with 4 x 5 mL of dry THF under an argon atmosphere. 3.5 mL of dry THF was added to this resin followed by KHMDS in toluene (0.5 M, 1.8 mL, 0.90 mmol) and gently mixed at room temperature for 45 min. The reaction mixture was quickly filtered under an argon atmosphere and allyl bromide (265 μ L, 1.8 mmol) in 5 mL dry THF was added and gently mixed for 24 hr. This reaction mixture was filtered, washed 3x THF/H₂O 2:1, 3x THF, 3x DCM, 3x alternating MeOH and DCM, and 4x DCM to give resin **6**.

[00259] Still referring to Scheme 3, resin **6** was washed 3x THF/H₂O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3x THF/H₂O 2:1, 3x THF, and 4x DCM. This resin was immediately treated with 95% TFA/H₂O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated *in vacuo*. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70°C. This reaction mixture was cooled and extracted 3x with EtOAc. The aqueous layer was concentrated to a puddle and redissolved in 5 mL 1 N HCl and filtered over a plug of Dowex® 50WX8 ion exchange resin in the acidic form. This plug was washed with H₂O and then the desired product was eluted with 2 N NH₄OH. The basic solution was concentrated *in vacuo* to dryness and the residue was dissolved in 10 mL 1 N HCl and lyophilized to give 24 mg of compound **1c**, the chemical structure of which is illustrated

above. MS (LC/MS, ESI): 216 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 2.5-2.7 (m, 2H), 1.9 (t, 2H), 1.4-1.6 (m, 4H), 0.7 (t, 2H).

Example 4a. Solid-Phase Synthesis of
2-Amino-6-(borono-2-(3-phenoxypropyl)hexanoic
acid hydrochloride (1d)



[00260] Compound **1d**, depicted above, was synthesized from resin **3** as illustrated in Scheme 4. Resin **3** (502 mg, 0.33 mmol) was treated with 3-phenoxypropyl bromide (0.525 μ L, 3.3 mmol), TBAI (1.23 g, 3.3 mmol), and BTPP (1.01 mL, 3.3 mmol) in 5 mL NMP at room temperature for 24 hr. The resin was filtered, washed 3x with DCM, 3x with alternating MeOH and DCM, 3x with MeOH, then 4x with DCM to give resin **7**. This was further washed 3x THF/H₂O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3x THF/H₂O (2:1), 3x THF, and 4x DCM. The resulting hydrochloride salt was neutralized by treating the resin with 10% DIEA/DCM for 5 minutes and resin **8** was washed 3x with DCM, 3x with alternating MeOH and DCM, 3x with MeOH, then 4x with DCM.

[00261] Still referring to Scheme 4, 3,4-dichlorobenzaldehyde (0.87 g, 5.0 mmol) was dissolved in 6 mL of trimethylorthoformate/NMP (2:1), added to resin **8**, and mixed overnight. The resin was filtered and washed 3x DCM, 3x alternating MeOH and DCM, 3x with DCM to give resin **9**. This was further treated with compound **4a** (1.02 g, 3.3 mmol) and BTPP (1.01 mL, 3.3 mmol) in 5 mL NMP for 24 hr. This resin was filtered, washed 3x with DCM, 3x with alternating MeOH and DCM, 3x with MeOH, then 4x with DCM to give resin **10**.


[00262] Next, resin **10** was washed 3x THF/H₂O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3x THF/H₂O 2:1, 3x THF, and 4x DCM.

This resin was immediately treated with 95% TFA/H₂O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated *in vacuo*. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70 °C. This reaction mixture was cooled and extracted 3x with EtOAc. The aqueous layer was concentrated to a puddle and redissolved in 5 mL 1 N HCl and filtered over a plug of Dowex® 50WX8 ion exchange resin in the acidic form. This plug was washed with H₂O and then the desired product, compound **1d**, was eluted with 2 N NH₄OH. The basic solution was concentrated *in vacuo* to dryness and the residue was dissolved in 10 mL 1 N HCl and lyophilized to give 23 mg of compound **1d**, the chemical structure of which is illustrated above. MS (LC/MS, ESI): 292 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 7.0-7.4 (m, 5H), 3.8 (m, 2H), 1.9 (m, 4H), 1.4-1.6 (m, 6H), 0.7 (t, 2H).

Example 4b. Solution-Phase Synthesis of
2-Amino-6-(borono-2-(3-phenoxypropyl)hexanoic
acid hydrochloride (1d)

[00263] As an alternative to the solid-phase synthesis of compound **1d** described above, it was also be made by the reaction scheme outlined in Scheme 8 (wherein R¹ = phenoxypropyl).


tert-Butyl 2-(diphenylmethyleamino)-
 5-phenoxypentanoate (**20d**)



20d


[00264] Referring to Scheme 8, compound **20d**, 0.60 g (69%), was obtained using General Procedure B, described above. MS (LC/MS, ESI): 430 (M+H), 374 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 15H), 4.0 (t, 1H), 3.9 (t, 2H), 2.2 (m, 2H), 1.8 (m, 2H), 1.4 (s, 9H).

tert-Butyl 2-(diphenylmethyleneamino)-
2-(3-phenoxypropyl)hex-4-enoate (**21d**)



[00265] Next, compound **21d**, 0.56 g (83%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 484 (M+H), 428 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 15H), 5.4 (m, 2H), 4.3-3.9 (m, 2H), 2.5-2.7 (m, 2H), 2.1 (m, 2H), 2.0 (d, 3H), 1.4 (s, 9H).

tert-Butyl 2-(diphenylmethyleneamino)-2-(3-phenoxypropyl)-
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)hexanoate (**19d**)



[00266] Thereafter, 0.08 g (40%) of **19d** was obtained using General Procedure E, described above. MS (LC/MS, ESI): 612 (M+H), 556 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 15H), 3.8-4.0 (m, 2H), 3.5 (m, 2H), 2.2 (m, 2H), 1.4-1.8 (m, 4H), 1.5 (s, 9H), 1.2 (s, 12H), 0.8 (t, 2H).

[00267] Finally, boronate ester **19d** was hydrolyzed to produce 2-amino-6-borono-2-(3-phenoxypropyl)hexanoic acid trifluoroacetate in a method similar to that illustrated in Scheme 8. This compound, 10 mg as a clear glass, was obtained using General Procedure F, with the following modification: The final compound was purified by reverse-phase HPLC on a C₁₈ column by eluting with a gradient of acetonitrile/water with 0.075% added TFA. Accordingly, the trifluoroacetic acid salt was isolated (not the hydrochloride). MS (LC/MS, ESI): 292 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 7.3-7.5 (m, 5H), 4.0 (t, 2H), 3.4 (m, 2H), 1.8-1.9 (m, 6H), 1.4-1.6 (m, 4H), 0.7 (t, 2H). The TFA addition salt may be readily converted to the hydrochloride salt, i.e., compound **1d**, using conventional acid/base extraction methods.

Examples 5 – 23

[00268] The following compounds listed in Table 1, below, were synthesized in analogous manner as described above for compound **1d**. In Table 1, each compound has the following chemical structure (each example in the Table has a different R¹ group):






















Table 1.

Example No.	Compound No.	R ¹	Amount Isolated	MS Data	Physical Appearance
5	1e		47 mg	290	Clear glass
6	1f		20 mg	344	White flocculent powder
7	1g		20 mg	340	White flocculent powder
8	1h		50 mg	328	White flocculent powder
9	1i		16 mg	355	Slight tan powder
10	1j		12 mg	354	Clear glass
11	1k		8 mg	378	White powder
12	1l		8 mg	340	White powder
13	1m		19 mg	402, 384	Light tan powder
14	1n		5 mg	352, 334	Clear glass
15	1o		8 mg	386, 368	Clear glass
16	1p		18 mg	386, 368	Clear glass
17	1q		23 mg	379, 360	Light tan powder


19	1s		2.5 mg	410, 392	White powder
21	1u		12 mg	346, 238	White powder
22	1v		15 mg	324, 306	White powder
23	1w		20 mg	324, 306	White powder

Example 24. 4-(4-Amino-8-borono-4-carboxyoctyloxy)benzoic acid hydrochloride (**1x**)




[00269] Compound **1x**, 100 mg as a clear glass, was synthesized using General Procedure F, described above. MS (LC/MS, ESI): 336 (M-H₂O+H), 354 (M+H).

Example 25. 2-Amino-2-(3-(4-aminophenoxypropyl)-6-borohexanoic acid trifluoroacetate (**1y**)




[00270] Compound **1y** was obtained by treating 150 mg of compound **19i**, illustrated below, with HOAc/H₂O/THF (1:1:1) for 1 hr. Next, 90 mg of the intermediate was subjected to catalytic transfer hydrogenation (to reduce the nitro group to an amino group) in methanol with 25 mg 10% Pd/C and 0.6 g ammonium formate at room temperature for 15 minutes.



[00271] The catalyst was filtered and the solution concentrated to dryness *in vacuo* to give a residue that was subjected to 6 N HCl at 70°C for 5 hr. This reaction mixture was concentrated to dryness and compound **1y** was eluted on a C₁₈ column with an acetonitrile/water gradient with 0.075% TFA present. After lyophilization of the fractions, 27 mg of compound **1y** was obtained as a light tan powder. MS (LC/MS, ESI): 307 (M-H₂O+H), 325 (M+H).

Example 26. *2-Amino-6-(borono-2-(pyridin-3-ylmethyl)hexanoic acid hydrochloride (1z)*




[00272] Compound **1z** was synthesized from resin **5** as illustrated in Scheme 5 (wherein R¹ = pyridylmethyl). Resin **5** (0.504 g, 0.30 mmol) was washed 3x THF/H₂O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3x THF/H₂O (2:1), 3x THF, and 4x DCM. The resulting hydrochloride salt was neutralized by treating the

resin with 10% DIEA/DCM for 5 min and resin **11** was washed 3x with DCM, 3x with alternating MeOH and DCM, 3x with MeOH, and then 4x with DCM.

[00273] Next, 3,4-dichlorobenzaldehyde (0.71 g, 4.1 mmol) was dissolved in 6 mL of trimethylorthoformate/NMP (2:1), and it was added to resin **11** and mixed overnight. The resin was filtered and washed 3x DCM, 3x alternating MeOH and DCM, 3x with DCM to give resin **12**, as illustrated in Scheme 5. This was further treated with 3-(bromomethyl)pyridine hydrobromide (0.152 g, 0.60 mmol) and BTTP (0.36 mL, 1.20 mmol) in 5 mL NMP for 24 hr. This resin was filtered, washed 3x with DCM, 3x with alternating MeOH and DCM, 3x with MeOH, then 4x with DCM to give resin **13**.

[00274] Still referring to Scheme 5, resin **13** was washed 3x THF/H₂O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3x THF/H₂O 2:1, 3x THF, and 4x DCM. This resin was immediately treated with 95% TFA/H₂O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated *in vacuo*. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70°C. This reaction mixture was cooled and extracted 3x with EtOAc. The aqueous layer was concentrated to a puddle and redissolved in 5 mL 1 N HCl and filtered over a plug of Dowex® 50WX8 ion exchange resin in the acidic form. This plug was washed with H₂O and then the desired product was eluted with 2 N NH₄OH. The basic solution was concentrated *in vacuo* to dryness and the residue was dissolved in 10 mL 1 N HCl and lyophilized to give 50 mg of compound **1z**. MS (LC/MS, ESI): 249 (M-H₂O+H); 231 (M-2H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 8.65 (d, 2H), 8.6 (s, 1H), 8.4 (d, 1H), 8.0 (m, 1H), 3.2-3.5 (m, 2H), 1.9 (m, 4H), 1.4-1.6 (m, 6H), 0.7 (t, 2H).


Example 27. *2-Amino-2-(benzyloxyethyl)-6-boronohexanoic acid hydrochloride (1aa)*



1aa

[00275] Compound **1aa**, illustrated above, was synthesized by the following procedure.


tert-Butyl 3-(benzyloxy)-2-(diphenylmethyleamino)butanoate (**20aa**)



20aa

[00276] Compound **20aa**, 0.37 g (86%), was obtained using General Procedure B, described above. MS (LC/MS, ESI): 430 (M+H), 374 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 15H), 4.6 (m, 2H), 3.9 (t, 1H), 3.4 (t, 2H), 2.2 (m, 2H), 1.4 (s, 9H).


tert-Butyl 2-(benzyloxyethyl)-2-(diphenylmethyleamino)hex-4-enoate (**21aa**)



21aa

[00277] Compound **21aa**, 0.37 g (80%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 484 (M+H), 428 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 15H), 5.4 (m, 2H), 4.7 (m, 2H), 3.4 (t, 2H), 2.5-2.8 (m, 2H), 2.1 (m, 2H), 2.0 (d, 3H), 1.4 (s, 9H).

tert-Butyl 2-(benzyloxyethyl)-2-(diphenylmethyleamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)hexanoate (**19aa**)



[00278] Compound **19aa**, 0.23 g (47%), was obtained using General Procedure E, described above. MS (LC/MS, ESI): 612 (M+H), 556 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 15H), 4.7 (m, 2H), 3.8-4.0 (m, 2H), 3.4 (t, 2H), 2.2 (m, 2H), 1.4-1.8 (m, 4H), 1.5 (s, 9H), 1.2 (s, 12H), 0.8 (t, 2H).

[00279] Finally, compound **1aa**, the structure of which is illustrated above, 68 mg (53%), was obtained using General Procedure F, described above. MS (LC/MS, ESI): 292 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 7.3-7.5 (m, 5H), 4.5 (s, 2H), 3.4 (m, 2H), 1.8-1.9 (m, 4H), 1.4-1.6 (m, 4H), 0.7 (t, 2H).

Examples 28 – 35

[00280] The following compounds listed in Table 2, below, were synthesized in analogous manner as described above for compound **1aa**. In Table 2, each compound has the following chemical structure (each example in the Table has a different R¹ group):





Table 2.


Example No.	Compound No.	R ¹	Amount Isolated	MS Data	Physical Appearance
28	1ab		100 mg	234, 216	Clear glass
29	1ac		19 mg	310, 292	Clear glass
30	1ad		70 mg	330, 312	Light tan powder
31	1ae		30 mg	354, 336	Light tan powder
32	1af		8 mg	324, 306	Clear glass
33	1ag		31 mg	326, 308	Clear glass
34	1ah		9 mg	341, 323	Light yellow powder
35	1ai		12 mg	445, 427	Clear glass

Example 36. 2-Amino-2-(2-(3-aminophenoxy)ethyl)-6-boronohexanoic acid hydrochloride (**1aj**)



1aj


[00281] Compound **19aj** (88 mg), illustrated below, was dissolved in 3 mL THF and 20 mg of 10% Pd/C was added followed introducing a H₂ atmosphere over the reaction mixture.



19aj

[00282] This was stirred at room temperature for 4 hr. The hydrogenation reaction reduced the imine to a secondary amine and the nitro group to an amino group. The reaction mixture was filtered over Celite® brand diatomaceous earth and the solvent removed *in vacuo*. The residue was redissolved in THF with 0.5 mL of 1 N HCl added and placed in a Parr hydrogenation apparatus with 50 mg of 10% Pd/C. 50 psi of H₂ gas was introduced and the reaction mixture was vigorously shaken for 18 hr. The reaction mixture was again filtered over Celite® brand diatomaceous earth and the solvent concentrated *in vacuo* and the residue was dissolved in 6 M HCl with heating for 4 hr to give 20 mg of compound **1aj** as a light tan solid. MS (LC/MS, ESI): 293 (M-H₂O+H) 311 (M+H).


Example 37. *2-Amino-6-borono-2-(3-hydroxypropyl)hexanoic acid hydrochloride (1ak)*



1ak

[00283] Compound **1ak**, illustrated above, was synthesized by the following procedure.


tert-Butyl 3-(benzyloxy)-2-(diphenylmethyleamino)-5-(tetrahydro-2H-pyran-2-yloxy)pentanoate (**20ak**)



20ak

[00284] Compound **20ak**, 0.44 g (50%), was obtained using General Procedure B, described above. MS (LC/MS, ESI): 438 (M+H), 382 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 4.9 (m, 1H), 4.0 (m, 1H), 3.8 (m, 2H), 3.4 (m, 2H), 2.1 (m, 2H), 1.3-2.0 (m, 8H), 1.4 (s, 9H).


tert-Butyl 2-(diphenylmethyleneamino)-2-(3-(tetrahydro-2H-pyran-2-yloxy)propyl)hex-4-enoate (**21ak**)



21ak

[00285] Compound **21ak**, 0.44 g (90%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 492 (M+H), 436 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 10H), 5.4 (m, 2H), 4.9 (m, 1H), 3.4-3.8 (m, 4H), 2.2-2.5 (m, 2H), 2.0 (d, 3H), 1.4 (s, 9H), 1.3-2.0 (m, 8H).

tert-Butyl 2-(diphenylmethyleneamino)-2-(3-(tetrahydro-2H-pyran-2-yloxy(propyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)hexanoate (**19ak**)




19ak

[00286] Compound **19ak**, 0.32 g (58%), was obtained using General Procedure E, described above. MS (LC/MS, ESI): 620 (M+H), 564 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 10H), 4.9 (m, 1H) 4.4 (m, 2H), 3.5-4.0 (m, 4H), 2.2 (m, 2H), 1.4-1.8 (m, 4H), 1.5 (s, 9H), 1.3-2.0 (m, 8H). 1.2 (s, 12H), 0.8 (t, 2H).

[00287] Finally, 75 mg (54%) of compound **1ak**, the structure of which is illustrated above, was obtained using General Procedure F, described above. MS (LC/MS, ESI): 216


(M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 3.6 (m, 2H), 2.0 (m, 2H) 1.4-1.8 (m, 8H), 0.8 (t, 2H).

Example 38. 2-Amino-6-borono-2-(4-boronobutyl)hexanoic acid (**1al**)




[00288] Compound **1al**, illustrated above, was synthesized by the following procedure.

tert-Butyl 2-(diphenylmethyleamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (**20al**)



[00289] Compound **18al**, 0.66g (69%), was obtained using General Procedure B, described above. MS (LC/MS, ESI): 478 (M+H), 422 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 4.0 (m, 1H), 2.0 (m, 2H), 1.4 (s, 9H), 1.3-1.7 (m, 4H), 1.2 (s, 12H), 0.9 (t, 2H).


tert-Butyl 2-(diphenylmethyleneamino)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl)hex-4-enoate (**21al**)



21al

[00290] Compound **21al**, 0.36g (49%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 532 (M+H), 476 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 10H), 5.4 (m, 2H), 2.5-2.8 (m, 2H), 2.0-2.1 (m, 2H), 2.0 (d, 3H), 1.3-1.7 (m, 4H), 1.4 (s, 9H), 1.2 (s, 12H), 0.9 (t, 2H).

tert-Butyl-2-(diphenylmethyleneamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl)hexanoate (**19al**)




19al

[00291] Compound **19al**, 75 mg (34%), was obtained using General Procedure E, described above. MS (LC/MS, ESI): 660 (M+H), 604 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 10H), 2.0-2.1 (m, 4H), 1.3-1.7 (m, 8H), 1.4 (s, 9H), 1.2 (s, 24H), 0.9 (t, 2H), 0.85 (t, 2H).

[00292] Finally, 12 mg (35%) of compound **1al** was obtained using General Procedure F, described above. MS (LC/MS, ESI): 240 (M-2H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 2.0 (m, 4H) 1.4-1.8 (m, 8H), 0.8 (t, 4H).


Example 39. *2-Amino-2-(4-boronobutyl)hex-4-enoic acid hydrochloride (1am)*



1am

[00293] Compound **1am**, 15 mg (20%), was obtained from **21al**, discussed above, using General Procedure F, described above. MS (LC/MS, ESI): 212 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 5.4 (m, 2H), 1.9-2.1 (m, 2H), 2.0 (d, 3H), 1.4-1.8 (m, 6H), 0.9 (t, 2H).


Example 40. *2-Amino-6-borono-2-(2-(2-methoxyethoxy)ethyl)hexanoic acid hydrochloride (1an)*



1an

[00294] Compound **1an**, illustrated above, was synthesized by the following procedure.


tert-Butyl 2-(diphenylmethyleneamino)-
4-(2-methoxyethoxy)butanoate (**20an**)



20an

[00295] Compound **20an**, 0.58 g (36%), was obtained using General Procedure B, described above. MS (LC/MS, ESI): 398 (M+H), 342 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 4.1 (t, 1H), 3.5 (s, 3H), 3.2-3.4 (br s, 6H), 2.2 (m, 2H), 1.4 (s, 9H).


tert-Butyl 2-(diphenylmethyleneamino)-
2-(2-(2-methoxyethoxy)ethyl)hex-4-enoate (**21an**)



21an

[00296] Compound **21an**, 0.40g (61%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 452 (M+H), 396 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 5.4 (m, 2H), 3.5 (s, 3H), 3.2-3.4 (br s, 6H), 2.5 (m, 2H), 2.2 (m, 2H), 2.0 (d, 3H), 1.4 (s, 9H).


tert-Butyl 2-(diphenylmethyleneamino)-2-(2-(2-methoxyethoxy)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (**19an**)



[00297] Compound **19an**, 0.31g (60%), was obtained using General Procedure D, described above. MS (LC/MS, ESI): 580 (M+H), 524 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 3.5 (s, 3H), 3.2-3.4 (br s, 6H), 2.5 (m, 2H), 2.2 (m, 2H), 1.4 (s, 9H), 1.3-1.7 (m, 4H), 1.2 (s, 12H), 0.9 (t, 2H).


[00298] Finally, 35 mg (21%) of compound **1an** was obtained using General Procedure F, described above. MS (LC/MS, ESI): 260 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 3.5 (s, 3H), 3.2-3.4 (br 2, 6H), 2.5 (m, 2H), 1.9-2.1 (m, 2H), 1.4-1.8 (m, 4H), 0.8 (t, 2H).

Example 41. 2-Amino-6-borono-2-methylhexanoic acid hydrochloride (1ao)



[00299] Compound **1ao**, illustrated above, was synthesized by the following procedure.


(S)-*tert*-Butyl 2-(diphenylmethyleneamino)propanoate (**20ao**)



20ao

[00300] Compound **20ao**, 1.76 g (91%), was obtained using General Procedure A, described above. MS (LC/MS, ESI): 310 (M+H), 254 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 4.1 (m, 1H), 1.5 (d, 3H), 1.4 (s, 9H).


tert-Butyl 2-(diphenylmethyleneamino)-
2-methylhex-4-enoate (**21ao**)



21ao

[00301] Compound **21ao**, 0.61 g (82%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 364 (M+H), 308 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 5.4 (m, 2H), 2.5-2.8 (m, 2H), 2.1 (d, 3H), 1.6 (s, 3H), 1.4 (s, 9H).

tert-Butyl 2-(diphenylmethyleneamino)-2-methyl-
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)hexanoate (**19ao**)




19ao

[00302] Compound **19ao**, 0.49 g (59%), was obtained using General Procedure E, described above. MS (LC/MS, ESI): 492 (M+H), 436 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 2.0 (m, 2H), 1.6 (s, 3H), 1.4 (s, 9H), 1.3-1.5 (m, 4H), 1.2 (s, 12H), 0.9 (t, 2H).


[00303] Finally, compound **1ao**, 82 mg (38%), was obtained using General Procedure F, described above. MS (LC/MS, ESI): 172 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 1.9-2.1 (m, 2H), 1.4 (s, 3H), 1.4 (m, 2H), 1.1 (m, 2H), 0.8 (t, 2H).

Example 42. *2-Amino-6-borono-2-isobutylhexanoic acid hydrochloride (1ap)*




[00304] Compound **1ap**, illustrated above, was synthesized by the following procedure.

(S)-tert-Butyl 2-(diphenylmethyleamino)-4-methylpentanoate (20ap)



[00305] Compound **20ap**, 0.79 g (100%), was obtained using General Procedure A, described above. MS (LC/MS, ESI): 352 (M+H), 296 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 4.0 (m, 1H), 1.9 (m, 2H), 1.7 (m, 1H), 1.5 (d, 3H), 1.4 (s, 9H), 0.8 (dd, 6H).


tert-Butyl 2-(diphenylmethyleamino)-
2-isobutyhex-4-enoate (**21ap**)



21ap

[00306] Compound **21ap**, 0.70 g (81%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 406 (M+H), 350 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 5.4 (m, 2H), 2.5-2.8 (m, 2H), 2.1 (d, 3H), 1.9 (m, 2H), 1.7 (m, 1H), 1.4 (s, 9H), 0.9 (dd, 6H).

tert-Butyl 2-(diphenylmethyleneamino)-
2-isobutyl-6-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)hexanoate (**19ap**)




19ap

[00307] Compound **19ap**, 0.51 g (58%), was obtained using General Procedure E, described above. MS (LC/MS, ESI): 534 (M+H), 478 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 1.9-2.1 (m, 4H), 1.7 (m, 1H), 1.4 (s, 9H), 1.3-1.5 (m, 4H), 1.2 (s, 12H), 0.9 (dd, 6H), 0.8 (t, 2H).


[00308] Finally, compound **1ap**, 0.16 g (63%), was obtained using General Procedure F, described above. MS (LC/MS, ESI): 214 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 1.9-2.1 (m, 4H), 1.4-1.8 (m, 5H), 0.9 (dd, 6H), 0.7 (t, 2H).

Example 43. *2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid hydrochloride (1aq)*




[00309] Compound **1aq**, illustrated above, was synthesized by the following procedure.

(S)-Methyl 3-tert-butoxy-2-(diphenylmethyleneamino)propanoate (20aq)




[00310] Compound **20aq**, 0.71 g (88%), was obtained using General Procedure A, described above. MS (LC/MS, ESI): 340 (M+H), 284 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 4.2 (m, 1H), 3.9 (m, 2H), 3.75 (s, 3H), 1.25 (s, 9H).

Methyl 2-(tert-butyloxymethyl)-2-(diphenylmethyleneamino)hex-4-enoate (21aq)



[00311] Compound 21aq, 0.67 g (82%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 393 (M+H), 338 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 5.4 (m, 2H), 3.9-4.1 (m, 2H), 3.75 (s, 3H), 2.5-2.8 (m, 2H), 2.1 (d, 3H), 1.25 (s, 9H).

Methyl 2-(tert-butyloxymethyl)-2-(diphenylmethyleneamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (19aq)




[00312] Compound **19aq**, 0.55 g (63%), was obtained using General Procedure E, described above. MS (LC/MS, ESI): 522 (M+H), 466 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 3.9-4.1 (m, 2H), 3.75 (s, 3H), 2.0 (m, 2H), 1.3-1.5 (m, 4H), 1.25 (s, 9H), 1.2 (s, 12H), 0.9 (t, 2H).

[00313] Finally, compound **1aq**, 29 mg (56%), was obtained using General Procedure F, described above. MS (LC/MS, ESI): 170 (M-2H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 3.9-4.1 (dd, 2H), 1.6-1.8 (m, 2H), 1.3 (m, 2H), 1.1 (m, 2H), 0.7 (t, 2H).


Examples 44 and 45.

(R)-2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid (**1ar**) and
(S)-2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid (**1as**)



[00314] Both of compounds **1ar** and **1as** were prepared in analogous manner as the compounds synthesized in Scheme 15, as described in detail below.

(S)-tert-Butyl 2-(naphthalene-1-yl)-
 4,5-dihydrooxazole-4-carboxylate (**46**)


**46**

[00315] 1-Naphthoyl chloride (0.97 g, 5.1mmol) and ser-OtBu HCl (1.00 g, 5.06 mmol) were dissolved in 30 mL dry DCM and Et₃N (1.5 mL, 10.76 mmol) was added. The reaction mixture was stirred for 4 hr at room temperature, diluted with DCM, washed 3x with 1 N HCl, 1x with brine and dried over dried over MgSO₄, filtered and concentrated to dryness *in vacuo* to give 1.51 g (100%) of a white solid. MS (LC/MS, ESI): 316 (M+H), 250 (M-tBu+H).

[00316] This reaction product was treated with (diethylamino)sulfur trifluoride (0.79 mL, 6.0 mmol) in 20 mL dry DCM under argon at -78°C for 2-8 hr. The cold solution was diluted with additional dry DCM and poured into sat NaHCO₃ solution and stirred at room temperature for 30 minutes. The layers were separated and the aqueous layer washed 3x with DCM, the organic layer was washed 1x with brine and dried over dried over MgSO₄, filtered and

concentrated to dryness *in vacuo*. The product was purified by silica gel chromatography by eluting with 1-10% ethyl acetate/hexane to give 0.99 g (66%) of compound **46** as an oil. MS (LC/MS, ESI): 298 (M+H), 242 (M-tBu+H).

(R)-tert-Butyl 4-(but-2-enyl)-2-(naphthalene-1-yl)-
4,5-dihydrooxazole-4-carboxylate (**47b**)




47b

[00317] Compound **46** (0.46 g, 1.5 mmol) was dissolved in 4 mL dry DCM under argon and 25 mg (0.033 mmol) of compound **45** and 0.93 g (7.68 mmol) crotyl bromide were added and the mixture cooled to 0°C. To this mixture was added 1.25 g (7.50 mmol) CsOH hydrate and the mixture was stirred vigorously at 0°C for 12-16 hr. The reaction was quenched with the addition of 5 mL 1 N HCl and diluted with additional DCM. The layers were separated and the organic layer washed 1x with 1 N HCl and 1 x with brine and dried over dried over MgSO₄, filtered and concentrated to dryness *in vacuo*. The product was purified by silica gel chromatography by eluting with 1-3% ethyl acetate/hexane to yield 0.24 g (46%) of compound **47b** as a clear oil. MS (LC/MS, ESI): 298 (M+H), 242 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.5-8.4 (m, 7H), 5.5 (m, 2H), 4-4.4 (m, 2H), 2.5-2.8 (m, 2H), 2.1 (d, 3H), 1.45 (s, 9H).

[00318] Chirality analysis of this product indicated that the enantiomeric excess was 40%. The opposite enantiomer was also obtained by the same procedure except that the opposite antipode for the catalyst was used.

[00319] Alternatively, both the *R* and *S* enantiomers of compound **47** were obtained by alkylation of compound **46** as follows. Compound **46** (0.82 g, 2.8 mmol) was dissolved in 10 mL dry DCM under argon. 0.42 mL (3.5 mmol) crotyl bromide, and 1.07 mL (3.5 mmol) BTTP were added. The mixture was stirred 12-16 hr at room temperature and then concentrated to dryness *in vacuo*. The product was purified by silica gel chromatography by eluting with

1-3% ethyl acetate/hexane to yield 0.93 g (96%) of racemic compound **47** as a clear oil. The enantiomers of compound **47** were separated on a ChiralPak AD-H chromatography column by eluting 500 mg of compound **47** with 10% ethanol/carbon dioxide to yield 79 mg of peak 1 (**47a**) and 150 mg of peak 2 (**47b**). Chiral analysis of these two products indicated that the enantiomeric excess was >98% for each.




48b

[00320] Compound **47b** (150 mg) was treated as described in General Procedure E, described above, to yield 120 mg of compound **48b**. MS (LC/MS, ESI): 480 (M+H), 424 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.5-8.4 (m, 7H), 4-4.4 (m, 2H), 2.0 (m, 2H), 1.3-1.5 (m, 4H), 1.25 (s, 9H), 1.2 (s, 12H), 0.9 (t, 2H).

[00321] Next, 120 mg (0.085 mmol) of compound **48b** was treated with 6 N HCl at 100°C for 12-16 hr. The solution was lyophilized to dryness to yield 57 mg of compound **1ar**, as a clear glass. MS (LC/MS, ESI): 234 (M+H), 216 (M-H₂O+H).


[00322] Compound **1as** (24 mg) was obtained as a clear glass in a similar fashion starting from compound **47a**.

Example 46. 2-Amino-2-(2-(benzyloxy)-2-oxoethyl)-6-borono-hexanoic acid hydrochloride (**1at**)




1at

[00323] Compound **1at**, illustrated above, was synthesized in accordance with the principles illustrated in Scheme 9, starting with compound **16c** (wherein R = *tert*-butyl). Compound **16c** (1.50 g, 5.10 mmol) was dissolved in 25 mL anhydrous DCM under argon. Crotyl bromide (1.00 mL, 8.26 mmol) and BTPP (2.30 mL, 7.50 mL) were added to the reaction mixture followed by stirring overnight at room temperature. Product **22** was purified by concentrating the reaction mixture to a puddle, redissolving it in a small amount of DCM, applying it to a dry silica gel column, and eluting it with mixtures of EtOAc/hexane (0.5-2%). MS (LC/MS, ESI): 350 (M+H), 295 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 10H), 5.4 (m, 2H), 4.0 (m, 1H), 2.5-2.8 (m, 2H), 2.0 (d, 3H), 1.4 (s, 9H).



21at

[00324] Compound **21at** (depicted above), 0.205 g (44%), was obtained using General Procedure C, also described above. MS (LC/MS, ESI): 498 (M+H), 442 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 15H), 5.4 (m, 2H), 5.2 (s, 2H), 2.8-3.2 (q, 2H), 2.5-2.8 (m, 2H), 2.0 (d, 3H), 1.4 (s, 9H).

**19at**

[00325] Still referring to Scheme 9, compound **19at** (depicted above), 0.130 g (51%), was obtained using General Procedure E, also described above. MS (LC/MS, ESI): 626 (M+H), 570 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 15H), 5.2 (s, 2H), 2.8-3.2 (q, 2H), 1.4-1.8 (m, 4H), 1.5 (s, 9H), 1.2 (s, 12H), 0.8 (t, 2H).

[00326] Finally, 29 mg (39%) of compound **1at** was obtained using General Procedure G, described above. MS (LC/MS, ESI): 306 (M-H₂O+H). ¹H NMR (300 MHz, D₂O, δ): 7.3-7.5 (m, 5H), 5.2 (s, 2H), 2.6-2.8 (q, 2H), 1.8-1.9 (m, 4H), 1.4-1.6 (m, 4H), 0.7 (t, 2H).

Examples 47 – 48

[00327] The following compounds listed in Table 3, below, were synthesized in analogous manner as described above for compound **1at**. In Table 3, each compound has the following chemical structure (each example in the Table has a different R¹ group):








Table 3.

Example No.	Compound No.	R ¹	Amount Isolated	MS Data	Physical Appearance
47	1au		30 mg	248, 230	Light tan solid
48	1av		19 mg	215, 197	Clear glass

Example 49. 2-Amino-6-borono-
2-(2-oxobutyl)hexanoic acid hydrochloride (**1aw**)

**1aw**


[00328] Compound **1aw** was synthesized in accordance with the principles illustrated in Scheme 7.

**19aw**

[00329] Referring to Scheme 7, compound **18** (wherein R = tBu, 240 mg, 0.50 mmol) was reacted with 1-bromobutan-2-one (80 mg, 0.525 mmol) using General Procedure C, described above, to give compound **19aw** (50 mg, 18%). MS (LC/MS, ESI): 548 (M+H), 492 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.2 (m, 10H), 3.0-3.2 (q, 2H), 2.5 (m, 2H), 1.4-1.8 (m, 4H), 1.5 (s, 9H), 1.2 (s, 12H), 1.1 (t, 3H), 0.8 (t, 2H).

[00330] Finally, 7 mg of compound **1aw** was obtained using General Procedure G, described above. MS (LC/MS, ESI): 227 (M-H₂O+H), 245 (M+H). ¹H NMR (300 MHz, D₂O, δ): 3.0-3.1 (q, 2H), 1.8-1.9 (m, 4H), 1.4-1.6 (m, 4H), 1.1 (t, 3H), 0.7 (t, 2H).


Example 50. *2-Amino-6-borono-2-(2-oxo-2-phenylethyl)hexanoic acid hydrochloride (1ax)*



1ax

[00331] Compound **1ax** (28 mg) was obtained as a clear glass using analogous procedures outlined above for compound **1aw**. MS (LC/MS, ESI): 276 (M-H₂O+H).


Example 51. *2-Amino-2-(2-(2-aminoethoxy)ethyl)-6-borohexanoic acid dihydrochloride (1ay)*



1ay

[00332] Compound **1ay** was synthesized in accordance with the principles illustrated in Schemes 8 and 11, as described in detail below.


tert-Butyl 4-(2-(bis(*tert*-butoxycarbonyl)amino)ethoxy)-
2-(diphenylmethyleneamino)butanoate (**20ay**)



20ay

[00333] Compound **20ay**, 0.99 g (85%), was obtained using General Procedure B, described above. MS (LC/MS, ESI): 583 (M+H), 527 (M-tBu+H), 483 (M-Boc+H). ¹H NMR (300 MHz, CDCl₃, δ 7.4-8.0 (m, 10H), 3.95 (t, 1H), 3.6 (t, 2H), 3.4 (m, 4H), 2.2 (m, 2H), 1.5 (s, 9H), 1.45 (s, 9H).


tert-Butyl 2-(2-(2-(bis(*tert*-butoxycarbonyl)amino)ethoxy)-
2-(diphenylmethyleneamino)hex-4-enoate (**21ay**)



21ay

[00334] Compound **21ay**, 0.90 g (83%), was obtained using General Procedure C, described above. MS (LC/MS, ESI): 637 (M+H), 581 (M-tBu+H), 537 (M-Boc+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 5.4 (m, 2H), 3.6 (t, 2H), 3.4 (m, 4H), 2.5 (m, 2H), 2.2 (m, 2H), 2.0 (d, 3H), 1.5 (s, 9H), 1.45 (s, 9H).

tert-Butyl 2-(2-(2-(bis(*tert*-butoxycarbonyl)amino)ethoxy)ethyl)-
2-(diphenylmethyleneamino)-6-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)hexanoate (**19ay**)



19ay

[00335] Compound **19ay**, 0.25 g (28%), was obtained using General Procedure E, described above. MS (LC/MS, ESI): 765 (M+H), 709 (M-tBu+H), 665 (M-Boc+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 3.6 (t, 2H), 3.4 (m, 4H), 2.5 (m, 2H), 2.2 (m, 2H), 1.4-1.8 (m, 4H), 1.5 (s, 9H), 1.45 (s, 9H), 0.8 (t, 2H).

[00336] Finally, 16 mg (73%) of compound **1ay** as a clear glass was obtained using General Procedure F, described above. MS (LC/MS, ESI): 263 (M+H), 245 (M-H₂O+H).

Examples 52 – 54

[00337] The following compounds listed in Table 4, below, were synthesized in analogous manner as described above for compound **1ay**. In Table 4, each compound has the following chemical structure (each example in the Table has a different R¹ group):





Table 4.

Example No.	Compound No.	R ¹	Amount Isolated	MS Data	Physical Appearance
52	1az		20 mg	301, 283	White flocculent powder
53	1ba		20 mg	302, 285	White powder
54	1bb		13 mg	247, 229	Clear glass

**Example 55. 2-Amino-6-borono-
2-(2-(2-(4-cyanobenzamido)ethoxy)ethyl)hexanoic
acid trifluoroacetate (38a)**

**38a**

[00338] Compound **38a** (8 mg as a white powder) was prepared from compound **19ay** in accordance with the principles illustrated in Schemes 12 and described in General Procedure J, described above. MS (LC/MS, ESI): 392 (M+H), 374 (M-H₂O+H).

Examples 56 – 67

[00339] The following compounds listed in Table 5, below, were synthesized in analogous manner as described above for compound **38a**. In Table 5, each compound has the following chemical structure (each example in the Table has a different R¹ group):










Table 5.

Example No.	Compound No.	R ¹	Amount Isolated	MS Data	Physical Appearance
56	38b		12 mg	304, 286	Light tan powder
57	39a		16 mg	412, 394	White powder
58	38c		7 mg	343	White powder
59	39b		6 mg	450, 432	Light tan powder
60	38d		6 mg	344, 326	Light tan powder
61	38e		6 mg	431, 413	White powder
62	39c		6 mg	451, 433	White powder

63	40a		26 mg	401, 383	White powder
64	38f		18 mg	387, 369	White powder
65	38g		12 mg	381, 363	White powder
66	38h		8 mg	289, 271	White powder
67	39d		17 mg	396, 378	White powder


Example 68. *2-Amino-4-(2-hydroxyguanidino)-2-methylbutanoic acid dihydrochloride (54a)*



54a

[00340] Compound **54a** was prepared in accordance with the synthesis illustrated in Scheme 16, wherein R¹ is a methyl group.


tert-Butyl 3-cyano-2-(diphenylmethyleamino)-
2-methyl propanoate (**49a**)



49a

[00341] Compound **49a**, 0.90 g (80%), was prepared from compound **20ao** using General Procedure C, described above. MS (LC/MS, ESI): 349 (M+H), 293 (M-tBu+H). ¹H NMR (300 MHz, CDCl₃, δ): 7.4-8.0 (m, 10H), 2.9-3.3 (m, 2H), 1.6 (s, 3H), 1.4 (s, 9H).

tert-Butyl 2-(*tert*-butoxycarbonylamino)-
3-cyano-2-methylpropanoate (**50a**)




50a

[00342] Compound **49a**, 500 mg (1.4 mmol), was treated with 2.5 mL 1 N HCl/THF (1:2) for 2 hr at room temperature. Ethyl acetate was added to the reaction mixture and the layers separated. The aqueous layer was washed two additional times with EtOAc and then the pH of the aqueous layer was adjusted to about 10 by the addition of 1 N NaOH. This aqueous solution was washed with DCM 3x and the DCM was concentrated to dryness *in vacuo* to give 250 mg of an oil. This was immediately dissolved in 3 mL THF and 340 mg (1.5 mmol) of di-*tert*-butyl dicarbonate was added. This mixture was stirred for 48 hr and ethyl acetate and 0.1 N HCl was added to the mixture. The layers were separated and the organic solution was washed 1x with brine, dried over MgSO₄, filtered and concentrated to dryness *in vacuo* to give an oil. This oil was purified by silica gel chromatography by eluting with mixtures of EtOAc/hexane (5-10%) to give purified compound **50a** (275 mg, 70%). MS (LC/MS, ESI): 285 (M+H), 229 (M-tBu+H).

^1H NMR (300 MHz, CDCl_3 , δ): 5.2 (m, 1H), 2.9-3.3 (m, 2H), 1.6 (s, 3H), 1.45 (s, 9H), 1.4 (s, 9H).


tert-Butyl 4-amino-2-(*tert*-butoxycarbonylamino)-
2-methylbutanoate hydrochloride (**51a**)



51a

[00343] In a Parr hydrogenation bottle, 240 mg of compound **50a** (0.84 mmol) was dissolved in 10 mL dry methanol and 0.84 mL of 1 N HCl was added to the solution. PtO_2 (50 mg) was added and a hydrogen gas atmosphere (60 psi) was introduced. The hydrogen atmosphere was recharged as needed to keep this pressure maintained and the reaction mixture was vigorously mixed for 24 hr. The reaction mixture was again filtered over Celite® brand diatomaceous earth, and the solvent concentrated *in vacuo* to give compound **51a** (270 mg, 100%) as a light brown solid. MS (LC/MS, ESI): 289 (M+H), 233 (M-tBu+H). ^1H NMR (300 MHz, DMSO- d_6 , δ): 2.7 (m, 2H), 2.3 (m, 2H), 1.6 (s, 3H), 1.45 (s, 9H), 1.4 (s, 9H).

tert-Butyl 2-(*tert*-butoxycarbonylamino)-
4-cyanamido-2-methylbutanoate (**52a**)




52a

[00344] Compound **51a**, 150 mg (0.462 mmol), was dissolved in 5 mL dry methanol and CNBr (53 mg, 0.51 mmol) and NaOAc (100 mg, 1.20 mmol) were added to this solution. The

reaction mixture was stirred for 48 hr at room temperature and an additional 10 mg of CNBr was added with continued stirring for 24 hr at room temperature. The reaction mixture was concentrated *in vacuo*, ethyl acetate and water were added to the solid residue, and the layers were separate and the aqueous solution washed 2x with ethyl acetate. The organic solution was washed 1x with brine, dried over MgSO₄, filtered and concentrated to dryness *in vacuo* to give compound 52a (140 mg, 99%) as a light brown solid. MS (LC/MS, ESI): 314 (M+H), 258 (M-tBu+H).

tert-Butyl 2-(*tert*-butoxycarbonylamino)-
4-(2-hydroxyguanidino)-2-methylbutanoate (**53a**)



53a

[00345] Compound **52a**, 94 mg (0.30 mmol), was dissolved in 4 mL dioxane and 40 mg of hydroxylamine hydrochloride (0.58 mmol) and 100 mg of Na₂CO₃ (1.20 mmol) were added to this solution. The reaction mixture was heated at 70°C for 4 hr, cooled to room temperature, and ethyl acetate and water was added to the reaction mixture. The layers were separated and the aqueous layer was washed 2x with EtOAc. The organic solution was washed 1x with brine, dried over MgSO₄, filtered and concentrated to dryness *in vacuo* to give a glassy residue. This product was purified by silica gel chromatography by eluting with 3% MeOH/DCM to give compound **53a** (60 mg, 58%) as a white glass. MS (LC/MS, ESI): 347 (M+H), 291 (M-tBu+H). ¹H NMR (300 MHz, CD₃OD, δ): 2.8 (m, 2H), 2.3 (m, 2H), 1.6 (s, 3H), 1.45 (s, 9H), 1.4 (s, 9H).

[00346] Finally, compound **54a** (40 mg) was obtained by treating compound **53a** with 6 N HCl/THF (1:1) at room temperature for 4 hr. The solvents were removed *in vacuo* to give a white glass. MS (LC/MS, ESI): 191 (M+H). ¹H NMR (300 MHz, D₂O, δ): 2.4 (m, 2H), 2.0 (m, 2H), 1.7 s, 3H).

Example 69. Biological Assay of Arginase Inhibition

[00347] Quantitative determination of arginase activity was performed by a colorimetric method using the QuantiChrom™ Arginase Assay Kit available from BioAssay Systems (Hayward, California, Catalog No. DARG-200), which was used according to the manufacture's protocol. Briefly, the method utilizes a chromogen that forms a colored complex specifically with urea produced in the arginase reaction. See, Mellerup, "Colorimetric method for rapid determination of serum arginase," Clin. Chem. 13, 900-08 (1967). The intensity of the color is directly proportional to the arginase activity in the sample.

[00348] The rate of urea production was measured in the presence of twelve different concentrations of each potential inhibitor compound. The half maximal inhibitory concentration (IC_{50}) was determined by constructing a dose-response curve. As IC_{50} values are dependent upon the measurement conditions, the IC_{50} values are converted to the inhibitor binding affinity (K_i) using the Cheng-Prusoff equation and the measured affinity constant (K_m) of L-arginine. See, e.g., Cheng et al., "Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction," Biochem. Pharmacol. 22, 3099-108 (1973).

[00349] The inhibitor binding affinities for both human arginase I and II ("hArgI" and "hArgII," respectively) are listed below in Table 6.

Table 6.

Compound No.	K_i	
	hArgI	hArgII
ABH	+++	+++
Rac-ABH	+++	++
Nor-NOHA	+	+
1a	+	+
1d	+++	+++
1aa	++	++
1ao	+++	++
1ap	++	++
1aq	+++	++
1aw	++	++

1ax	++	++
1e	++	++
1ad	++	++
1as	+	+
1ar	+++	+++
54a	+	+
1az	+++	+++
1ba	++	++
38b	+	+
39a	++	++
38a	++	++
1h	+++	++
39c	++	++
1bb	+++	+++
40a	++	++

“+++” = $10^{-10} < K_i < 10^{-8}$ M; “++” = $10^{-8} < K_i < 10^{-7}$ M; and “+” = $10^{-7} < K_i < 5 \times 10^{-7}$ M.
 “ABH” and “nor-NOHA” (illustrated in Scheme 18) and Rac-ABH (racemic ABH) are control samples.

[00350] In Table 6, the K_i values reflect the potency of these molecules to inhibit the catalytic activity of arginase to produce urea from the substrate L-arginine. Lower K_i values signify more effective enzyme inhibition. Those compounds with the lowest (most potent) to the highest K_i values (least potent) are identified by “+++,” “++,” and “+,” respectively. The potencies of these examples (except the non-racemic compounds compounds **1ar** and **1as**) should be compared to that of the closest prior art, racemic-ABH (“Rac-ABH”) in Table 6. That is, racemic materials were compared to racemic controls. Thus, there are several examples that have similar potencies to Rac-ABH. Furthermore, if one synthesizes the single enantiomers of one of these examples, compound **1aq**, and compares the potency to the active enantiomer of ABH, then one observes that one enantiomer (namely compound **1ar**) is not only as potent as ABH, but is significantly (almost two orders of magnitude) more potent than the other enantiomer (compound **1as**).

[00351] The structure-activity relationship for compound **1d** is noteworthy because the phenoxypropyl derivative is as potent as Rac-ABH. However, compound **1ak** without the aryl ring is less potent. If the phenoxy oxygen atom of compound **1d** is moved closer to the α -C by one atom while maintaining the same atom distance as in the benzylic ether of compound **1aa**, then potency is lost. In addition, replacing the phenoxy oxygen of compound **1d** by a carbon atom as in compound **1e** also results in a lost of potency. Shortening the alkyl chain by one

carbon atom as in the phenoxyethyl compound **1ad** also results in a potency loss. Thus, there appears to be definitive structure-activity features that results in increased potency at the molecular target, arginase, in these α,α -disubstituted derivatives.

[00352] In accordance with the foregoing observations, the R^1 groups can be selected to target binding interactions in the outer active site cleft and the region flanking the outer active site clefts of arginase I and II, such that the new compounds bind more tightly than their respective parent compounds. Furthermore, the $C\alpha-R^1$ groups in the compounds of formula Ia or formula Ib of the invention can be varied to alter pharmaceutically important properties, such as crystal phase or shelf stability, absorption, biodistribution, metabolism, excretion, water solubility, lipophilicity, and the like. The $C\alpha-R^1$ groups of the invention can also be varied to enhance influx or prevent efflux of the compound by cellular transport proteins.


[00353] Accordingly, those skilled in the art will appreciate that numerous changes and modifications can be made to these exemplary embodiments of the invention and that such changes and modifications can be made without departing from the spirit of the invention. Contemplated equivalents of the compounds described herein include compounds that otherwise correspond thereto and that have the same general properties thereof (e.g., functioning as arginase inhibitors), wherein one or more simple variations of substituents are made that do not adversely affect the therapeutic or diagnostic efficacy of the compound. In general, the compounds of the present invention may be prepared by the methods illustrated in the reaction schemes as, for example, described herein, or by modifications thereof, using readily available starting materials, reagents, and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned herein.

[00354] It will be appreciated by those skilled in the art that compounds of the invention may contain a chiral center, and they may be isolated in optically active or racemic forms. Some compounds may also exhibit polymorphism. It is therefore to be understood that the present invention encompasses any racemic, optically active, polymorphic, tautomeric, zwitterionic, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein.

[00355] It is, therefore, intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

What is claimed is:


1. A compound of formula IA:



IA

or a pharmaceutically-acceptable salt thereof;

wherein



X¹ is -(CH₂)-;

X² is -(CH₂)-;

X³ is -(CH₂)-;

X⁴ is -(CH₂)-;

R¹ is (C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₆-C₁₀)aryl(C₁-C₄)alkyl, (C₄-C₁₀)heteroaryl(C₁-C₄)alkyl, (C₂-C₁₀)heterocycloalkyl(C₁-C₄)alkyl, (C₆-C₁₀)aryloxy(C₁-C₄)alkyl, (C₄-C₁₀)heteroaryloxy(C₁-C₄)alkyl, -R^x-C(=O)-R^y, -R^x-O-R^z, -R^x-O-R^x-NR³R⁵, -R^x-NR³R⁵ or (C₁-C₄)alkyl-B-(OH)₂;

each R^x is independently (C₁-C₄)alkylenyl;

R^y is (C₁-C₄)alkyl, hydroxyl, (C₁-C₆)alkoxy or (C₆-C₁₀)aryl;


R^z is (C₁-C₄)alkyl;

R³ is H;

R⁴ is (C₁-C₄)alkyl or H; and

R⁵ is -C(=O)-(C₁-C₄)alkyl, -C(=O)-(C₆-C₁₀)aryl, -SO₂-(C₆-C₁₀)aryl, -C(=O)NR³R⁴ or -C(=O)-NR⁴(C₆-C₁₀)aryl.

2. The compound according to claim 1, wherein said compound of formula IA has the structure of a compound of formula Ia:



Ia

3. The compound according to claim 1, wherein

R^1 is (C₁-C₄)alkyl, hydroxy(C₁-C₃)alkyl, (C₃-C₄)alkenyl, (C₆)aryl(C₁-C₄)alkyl, (C₅)heteroaryl(C₁)alkyl, (C₄-C₅)heterocycloalkyl(C₃)alkyl, (C₆)aryloxy(C₂-C₃)alkyl, (C₆)heteroaryloxy(C₃)alkyl, $-R^x-C(=O)-R^y$, $-R^x-O-R^z$, $-R^x-O-R^x-NR^3R^5$, $-R^x-NR^3R^5$ or (C₄)alkyl-B-(OH)₂;

each R^x is independently (C₁-C₄)alkylenyl;

R^y is (C₂)alkyl, hydroxyl, (C₁)alkoxy or (C₆)aryl;

R^z is (C₂)alkyl;

R^3 is H;

R^4 is (C₁)alkyl or H; and

R^5 is $-C(=O)-(C_1)alkyl$, $-C(=O)-(C_6)aryl$, $-SO_2-(C_6)aryl$, $-C(=O)NR^3R^4$ or $-C(=O)-NR^4(C_6)aryl$.

4. The compound according to claim 3, wherein R^1 is (C₁)alkyl.

5. The compound according to claim 3, wherein R^1 is (C₂)alkyl.

6. The compound according to claim 3, wherein R^1 is (C₄)alkyl.

7. The compound according to claim 3, wherein R^1 is (C₃)alkenyl.


8. The compound according to claim 3, wherein R^1 is (C₄)alkenyl.

9. The compound according to claim 3, wherein R^1 is hydroxy(C₁)alkyl.


10. The compound according to claim 3, wherein R^1 is hydroxy(C₃)alkyl.

11. The compound according to claim 3, wherein R^1 is (C₆)aryl(C₁)alkyl.


12. The compound according to claim 3, wherein R^1 is (C_6) aryl (C_4) alkyl.
13. The compound according to claim 3, wherein R^1 is (C_4) heterocycloalkyl (C_3) alkyl.
14. The compound according to claim 3, wherein R^1 is (C_5) heterocycloalkyl (C_3) alkyl.
15. The compound according to claim 3, wherein R^1 is (C_6) aryloxy (C_2) alkyl.
16. The compound according to claim 3, wherein R^1 is (C_6) aryloxy (C_3) alkyl.
17. The compound according to claim 3, wherein each R^x is independently (C_1) alkylenyl.
18. The compound according to claim 3, wherein each R^x is independently (C_2) alkylenyl.
19. The compound according to claim 3, wherein each R^x is independently (C_4) alkylenyl.
20. A compound selected from the group consisting of:
2-Amino-2-benzyl-6-boronoheptanoic acid:




2-Allyl-2-amino-6-boronoheptanoic acid:




2-Amino-2-(4-boronobutyl)succinic acid:




2-Amino-6-(borono-2-(3-phenoxypropyl)heptanoic acid:




2-Amino-6-borono-2-(4-phenylbutyl)hexanoic acid:




2-Amino-6-borono-2-(3-(4-chlorophenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(4-methoxyphenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(4-fluorophenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(4-nitrophenoxy)propyl)hexanoic acid:




2-Amino-2-(3-(benzo[d][1,3]dioxol-5-yloxy)propyl)-6-borohexanoic acid:




2-Amino-6-borono-2-(3-(4-(trifluoromethyl)phenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(3-methoxyphenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(3-phenoxyphenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(3-isopropylphenoxy)propyl)hexanoic acid:




2-Amino-2-(3-(biphenyl-4-yloxy)propyl)-6-borohexanoic acid:




2-Amino-2-(3-(biphenyl-3-yloxy)propyl)-6-borohexanoic acid:




2-Amino-6-borono-2-(3-(3-(trifluoromethyl)phenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(4-(trifluoromethylthio)phenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(2,6-difluorophenoxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(*o*-tolylloxy)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(*p*-tolylloxy)propyl)hexanoic acid:




2-Amino-2-(3-(4-aminophenoxypropyl)-6-borono)hexanoic acid:




2-Amino-6-(borono-2-(pyridin-3-ylmethyl)hexanoic acid:




2-Amino-2-(benzyloxyethyl)-6-boronohexanoic acid:




2-Amino-6-borono-2-(2-methoxyethyl)hexanoic acid:




2-Amino-6-borono-2-(2-(*p*-tolyoxy)ethyl)hexanoic acid:




2-Amino-6-borono-2-(2-(3-chlorophenoxy)ethyl)hexanoic acid:




2-Amino-6-borono-2-(2-(3-methoxyphenoxy)ethyl)hexanoic acid:




2-Amino-6-borono-2-(2-(3-nitrophenoxy)ethyl)hexanoic acid:




2-Amino-6-borono-2-(2-(3-(morpholinosulfonyl)phenoxy)ethyl)hexanoic acid:




2-Amino-2-(2-(3-aminophenoxy)ethyl)-6-boronohexanoic acid:




2-Amino-6-borono-2-(3-hydroxypropyl)hexanoic acid:




2-Amino-6-borono-2-(4-boronobutyl)hexanoic acid:




2-Amino-2-(4-boronobutyl)hex-4-enoic acid:




2-Amino-6-borono-2-(2-(2-methoxyethoxy)ethyl)hexanoic acid:




2-Amino-6-borono-2-methylhexanoic acid:




2-Amino-6-borono-2-isobutylhexanoic acid:




2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid:




(*R*)-2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid:




(*S*)-2-Amino-6-borono-2-(hydroxymethyl)hexanoic acid:




2-Amino-2-(2-(benzyloxy)-2-oxoethyl)-6-borono-hexanoic acid:




2-Amino-6-borono-2-(2-methoxy-2-oxoethyl)hexanoic acid:




2-Amino-6-borono-2-(cyanomethyl)hexanoic acid:




2-Amino-6-borono-2-(2-oxobutyl)hexanoic acid:




2-Amino-6-borono-2-(2-oxo-2-phenylethyl)hexanoic acid:




2-Amino-2-(2-(2-aminoethoxy)ethyl)-6-boronohexanoic acid:




2-Amino-6-borono-2-(3-(piperidin-4-yl)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(piperazine-1-yl)propyl)hexanoic acid:




2,6-Diamino-2-(4-boronobutyl)hexanoic acid:




2-Amino-6-borono-2-(2-(2-(4-cyanobenzamid)ethoxy)ethyl)hexanoic acid:




2-(2-(2-Acetamidoethoxy)ethyl)-2-amino-6-boronohexanoic acid:




2-Amino-6-borono-2-(2-(2-(3-(3-methoxyphenyl)ureido)ethoxy)ethyl)hexanoic acid:




2-(3-(1-Acetylpiperidin-4-yl)propyl)-2-amino-6-borono-hexanoic acid:




2-(3-(4-Acetylpiperazin-1-yl)propyl)-2-amino-6-borono-hexanoic acid:




2-Amino-6-borono-2-(3-(4-(4-cyanobenzoyl)piperazine-1-yl)propyl)hexanoic acid:




2-Amino-6-borono-2-(3-(4-(3-methoxyphenylcarbamoyl)piperazin-1-yl)propyl)hexanoic acid:




2-Amino-6-borono-2-(4-(4-methylphenylsulfonamido)butyl)hexanoic acid:




2-Amino-6-borono-2-(4-(3,5-difluorobenzamido)butyl)hexanoic acid:



6-Acetamido-2-amino-2-(4-boronobutyl)hexanoic acid:




2-amino-6-borono-2-(4-(3-(3-methoxyphenyl)ureido)butyl)hexanoic acid:




or a pharmaceutically acceptable salt thereof.

21. A compound selected from the group consisting of:


4-(4-Amino-8-borono-4 carboxyoctyloxy)benzoic acid:




2-Amino-6-borono-2-(2-(2,3-dihydrobenzo[b][1,4]dioxin-5-yloxy)ethylhexanoic acid:




2-Amino-6-borono-2-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)hexanoic acid:



2-Amino-6-borono-2-(3-(1-(3-methoxyphenyl)carbamoyl)piperidin-4-yl)propyl)hexanoic acid:




2-Amino-6-(benzyloxycarbonylamino)-2-(4-boronobutyl)hexanoic acid:



; and

2-Amino-4-(2-hydroxyguanidino)-2-methylbutanoic acid:



or a pharmaceutically acceptable salt thereof.

22. The compound of any one of claims 1-21, wherein said pharmaceutically acceptable salt comprises one hydrochloric acid or trifluoroacetic acid addition salt of said compound.

23. A pharmaceutical composition, comprising a compound as defined in any one of claims 1-22, or a pharmaceutically acceptable salt thereof; and a pharmaceutically-acceptable carrier.

24. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for inhibiting arginase in a mammal.

25. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for preparation of a medicament for inhibiting arginase in a mammal.

26. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for treating an arginase-related disorder in a mammal.

27. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for preparation of a medicament for treating an arginase-related disorder in a mammal.


28. The use according to claim 26 or 27,
wherein the arginase-related disorder is a disorder associated with an abnormally low level of nitric oxide synthase activity in a tissue of the human, a disorder associated with an abnormally high level of arginase activity in a tissue of the human, or combinations thereof.
29. The use according to claim 26 or 27,
wherein said arginase-related disorder is heart disease, systemic hypertension, pulmonary hypertension, ischemia reperfusion injury, peripheral vascular disease, peripheral arterial disease, subarachnoid hemorrhage, erectile dysfunction, autoimmune encephalomyelitis, chronic renal failure, gastrointestinal motility disorders, gastric cancers, reduced hepatic blood flow, insufficient hepatic blood flow, cerebral vasospasm, or a combination thereof.
30. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for relaxing smooth muscle in a mammal.
31. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for preparation of a medicament for relaxing smooth muscle in a mammal.
32. The use according to claim 30 or 31,
wherein the smooth muscle which is relaxed is at least one selected from the group consisting of a gastrointestinal smooth muscle, anal sphincter smooth muscle, esophageal sphincter muscle, corpus cavernosum, sphincter of Oddi, arterial smooth muscle, heart smooth muscle, pulmonary smooth muscle, kidney smooth muscle, uterine smooth muscle, vaginal smooth muscle, cervical smooth muscle, placental smooth muscle, and ocular smooth muscle.
33. A use of a compound as defined in any one of claims 1-22 or a salt thereof for inhibiting arginase.
34. The use according to claim 33,
wherein said arginase is a yeast arginase, a bacterial arginase, a parasitic arginase, or a mammalian arginase.

35. The use according to claim 34,
wherein said mammalian arginase is a human type I arginase or a human type II arginase.
36. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for treating a disease or condition associated with upregulation of arginase in a mammal,
wherein said disease or condition is a gastrointestinal disease, a pulmonary inflammatory disease, a sexual arousal disorder, a cardiovascular disorder, a hemolytic disorder, an autoimmune disease, wound healing, a disease caused by parasitic protozoa, a disease caused by bacteria, a cancer, pre-term labor, psoriasis, or a combination thereof.
37. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for preparation of a medicament for treating a disease or condition associated with upregulation of arginase in a mammal,
wherein said disease or condition is a gastrointestinal disease, a pulmonary inflammatory disease, a sexual arousal disorder, a cardiovascular disorder, a hemolytic disorder, an autoimmune disease, wound healing, a disease caused by parasitic protozoa, a disease caused by bacteria, a cancer, pre-term labor, psoriasis, or a combination thereof.
38. The use according to claim 36 or 37,
wherein said gastrointestinal disease is a gastrointestinal motility disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, adenotonsillar disease, or a combination thereof.
39. The use according to claim 36 or 37,
wherein said pulmonary inflammatory disease is asthma, chemically-induced lung fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD) or a combination thereof.
40. The use according to claim 36 or 37,
wherein said sexual arousal disorder is male erectile dysfunction, Peyronie's Disease, or a female sexual arousal disorder.

41. The use according to claim 36 or 37,
wherein said cardiovascular disorder is endothelial vascular dysfunction in atherosclerosis, hypertension, ischemia reperfusion injury, peripheral vascular disease, peripheral arterial disease, subarachnoid hemorrhage, hypercholesterolemia, diabetes, diabetic cardiovascular disease, pulmonary arterial hypertension, Reynaud's disease or a combination thereof.
42. The use according to claim 36 or 37,
wherein said hemolytic disorder is paroxysmal nocturnal hemoglobinuria (PNH), sickle-cell disease, thalassemias, hereditary spherocytosis and stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, ABO mismatch transfusion reaction, paroxysmal cold hemoglobinuria, severe idiopathic autoimmune hemolytic anemia, infection-induced anemia, malaria, cardiopulmonary bypass, mechanical heart valve-induced anemia, chemical induced anemia, or a combination thereof.
43. The use according to claim 36 or 37,
wherein said autoimmune disease is encephalomyelitis, multiple sclerosis, antiphospholipid syndrome 1, autoimmune hemolytic anaemia, chronic inflammatory demyelinating polyradiculoneuropathy, dermatitis herpetiformis, dermatomyositis, myasthenia gravis, pemphigus, rheumatoid arthritis, stiff-person syndrome, type 1 diabetes, ankylosing spondylitis, or a combination thereof.
44. The use according to claim 36 or 37,
wherein said condition is wound healing.
45. The use according to claim 36 or 37,
wherein said disease caused by parasitic protozoa is African sleeping sickness, Chagas' disease, leishmaniasis, malaria, or a combination thereof.
46. The use according to claim 36 or 37,
wherein said cancer is renal cell carcinoma, prostate cancer, colorectal cancer, breast cancer, skin cancer, lung cancer, ovarian cancer, gastric cancer, or a combination thereof.

47. The use according to claim 46,
wherein said skin cancer is a squamous cell cancer, basal cell cancer, or a combination thereof.
48. The use according to claim 36 or 37,
wherein said condition is pre-term labor.
49. The use according to claim 36 or 37,
wherein said condition is psoriasis.
50. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for providing relief from immune suppression in a mammal,
wherein said mammal is suffering from a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.
51. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for preparation of a medicament for providing relief from immune suppression in a mammal,
wherein said mammal is suffering from a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.
52. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for inhibiting the production of ornithine in a mammal suffering from at least one tumor.
53. A use of a compound as defined in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for preparation of a medicament for inhibiting the production of ornithine in a mammal suffering from at least one tumor.

1 / 24



non-inhibitory lactone
"prodrug" form of the
inhibitor

active inhibitor
that fits in the
arginase active
site




FIG. 1

2 / 24





FIG. 2

3 / 24




FIG. 3

4 / 24




FIG. 4

5 / 24




FIG. 5

6 / 24




FIG. 6

7 / 24




FIG. 7

8 / 24




FIG. 8

9 / 24




FIG. 9




FIG. 10

11 / 24




FIG. 11

12 / 24




FIG. 12

13 / 24




FIG. 13

14 / 24




FIG. 14

15 / 24




FIG. 15

16 / 24




FIG. 16

17 / 24




FIG. 17

18 / 24




FIG. 18

19 / 24




FIG. 19

20 / 24




FIG. 20

21 / 24





FIG. 21


22 / 24



for example,
R* = halo,
alkyl, aryl,
alkoxy

FIG. 22

23 / 24




alkyl chain can be varied


The rings could also be piperidones and pyrrolidinones

FIG. 23

24 / 24



R = alkyl, aryl



R, R' = H, alkyl, heterocyclic



Ar = phenyl, substituted phenyl
thiophene

FIG. 24



non-inhibitory lactone
"prodrug" form of the
inhibitor

active inhibitor
that fits in the
arginase active
site

